

2015 Ishmael Lectureship



MAUREEN D. MAYES, MD, MPH | PRESENTER



PRESENT TITLE Professor of Internal Medicine
Elizabeth Bidgood Chair in Rheumatology
Division of Rheumatology and Clinical Immunogenetics

UNDERGRADUATE EDUCATION

1967 BA Degree (Chemistry), College of Notre Dame of Maryland,
Baltimore, MD

GRADUATE EDUCATION

1970-1973 Graduate Student, Department of Biochemistry, University of
Virginia, Charlottesville, VA

1976 MD Degree, Eastern Virginia Medical School, Norfolk, VA

1994 MPH Epidemiology, University of Michigan School of Public Health, Ann
Arbor, MI

OTHER TRAINING AND EXPERIENCE

1967-1968 Research Assistant, Biological Laboratories, Harvard University,
Cambridge, MA

1968-1969 Research Assistant, Virginia Associated Research Center of Virginia
Commonwealth University, Newport News, VA

POSTGRADUATE TRAINING

1977-1979 Internal Medicine Intern and Resident, Cleveland Clinic
Foundation, Cleveland, OH

1979-1981 Rheumatology Fellow, Cleveland Clinic Foundation, Cleveland, OH

ACADEMIC APPOINTMENTS

1981-1985	Assistant Professor of Medicine, Division of Rheumatology, West Virginia University School of Medicine, Morgantown, WV
1985-1990	Assistant Professor of Medicine, Division of Rheumatology, Wayne State University School of Medicine, Detroit, MI
1990-1997	Associate Professor of Medicine (Clinician - Educator), Division of Rheumatology, Wayne State University School of Medicine, Detroit, MI
1997-2002	Adjunct Associate Professor of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI
1997-2002	Professor of Medicine (Clinician - Educator), Division of Rheumatology, Wayne State University School of Medicine, Detroit, MI
2002-present	Professor of Medicine, Division of Rheumatology and Clinical Immunogenetics, University of Texas-Houston Health Science Center

HOSPITAL APPOINTMENTS

2002	Memorial Hermann Hospital LBJ Hospital
2004	MD Anderson Cancer Center
2004	St. Luke's Episcopal Hospital

LICENSURE

1977	Licensure – State of Virginia, No. 0101-027979 (Inactive)
1985	Licensure - State of Michigan, No. 4301-048422 (Inactive)
2002	Licensure – State of Texas, No. L 4562 (Active)

CERTIFICATION

1978	National Board of Medical Examiners
------	-------------------------------------

2015 Ishmael Lectureship



- 1980 American Board of Internal Medicine, No. 71012
- 1982 American Board of Internal Medicine, Subspecialty Board in Rheumatology, No. 71012

PROFESSIONAL ORGANIZATIONS (AND COMMITTEES OF THESE)

LOCAL AND REGIONAL:

- 1995-2001 Member, Board of Trustees, Michigan Chapter, Arthritis Foundation
- 1997-2001 Member, Community Advisory Committee, University of Michigan, Multipurpose Arthritis & Musculoskeletal Diseases Center
- 1992-1995 Member, Arthritis Subcommittee, Chronic Disease Advisory Committee, Michigan Department of Public Health
- 1988-1990, 1991-1996; 1998-2000, 2001-2002 Member, Michigan Chapter, Arthritis Foundation Medical and Scientific Committee
- 1986-2001 Member, Michigan Chapter, Scleroderma Foundation Medical Advisory Board
- 2000-2001 Member, Arthritis 2000 Plan Steering Committee of the Michigan Department of Community Health

NATIONAL:

- American College of Physicians, Fellow
American College of Rheumatology, Master
Scleroderma Clinical Trials Consortium (SCTC)
- 1999 - 2001 Member, American College of Rheumatology Abstract Review Committee for Scleroderma and Myopathies
- 1995-1997 Member, Central Region Council of the American College of Rheumatology
- 2009-2011 Co-Chair, American College of Rheumatology Abstract Review Committee for Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics.

NATIONAL ADVISORY COMMITTEES

- 2002 - 2004 Chair, Scientific Advisory Committee for the Childhood Onset Scleroderma Registry, funded by the Scleroderma Foundation, 2002 – 2004. Principal Investigator: Dr. Thomas Medsger, Jr., Professor of Internal Medicine, Division of Rheumatology, University of Pittsburgh
- 2002 - 2004 Member, Medical Advisory Board, Scleroderma Foundation (previously Chair 1996 – 2002)
- 2002 - 2005 Member, Advisory Committee for the ‘Michigan Study and Surveillance of Lupus,’ Michigan Dept of Community Health, funded by Centers for Disease Control, 2002
- 2001 - 2005 Co-Chair, Protocol Development Group for HDIT (High Dose Immunosuppressive Therapy) vs CTX (Cyclophosphamide) for severe Systemic Sclerosis, NIH/NIAID
- 2002 - 2005 Chair, Task Force for MicroArray Consortium, Scleroderma Foundation
- 2000 - 2005 Member, Executive Committee, Scleroderma Clinical Trials Consortium (past president)
- 2005 - 2008 Member, Data Safety Monitoring Board, “Study of Alefacept in Scleroderma Lung Disease: Role of T Cells” funded by Biogen-Idec.
- 2005 - 2008 Member, Data Safety Monitoring Board, Novartis Study CAAE581C2201
- 2007 - 2010 Member, External Advisory Panel of the SCCOR in Pulmonary Arterial Hypertension, Johns Hopkins University School of Medicine
- 2008 - 2012 Member (Chair as of 11/2009), Scientific Advisory Board for the NIH/NIAMS funded CLEAR (Consortium for the Longitudinal Evaluation of African-Americans with Early Rheumatoid Arthritis) Registry, University of Alabama Birmingham.
- 2010 - 2011 Member, Data Safety Committee, Novartis Study CBAF312
- 2010 Founding Member, World Scleroderma Foundation

2015 Ishmael Lectureship



- 2011- present Chair, International Scleroderma Clinical Care and Research (InSCAR) Committee (joint Committee of U.S., Chinese and European Collaborators)
- 2010 - present Member, Scleroderma Foundation National Medical Advisory Board Member
- 2013 - present Member, Treasurer, Scleroderma Clinical Trials Consortium

HONORS & AWARDS

Master of the American College of Rheumatology, November 2012
Elizabeth Bidgood Chair in Rheumatology, March 2011

Lifetime Achievement Award, national Scleroderma Foundation, July 2010

Spirit of Hope Award, national Scleroderma Foundation, October, 2006

Award for Best Poster (2 awards given from approximately 800 abstracts), Society of Behavioral Medicine Annual Meeting, San Diego, CA, March 6-9, 1999

Wayne State University School of Medicine, College Teaching Award, September 1998

Citation Paper Award, Biofeedback Society of America, March 1996

NIAMS Senior Research Fellowship, January 1994

Maureen D. Mayes, M.D., Award of Excellence, presented by the Southeast Michigan United Scleroderma Foundation, 1992

Women of Wayne Staff/Faculty Recognition Award-Honorable Mention, May 1990

Citation Paper Award, Biofeedback Society of America, March 1987

Lower Award (Rheumatology Research), Cleveland Clinic Foundation, 1981

2015 Ishmael Lectureship



Arthritis
Foundation™



The UNIVERSITY of OKLAHOMA
Health Sciences Center

J.J. Quarles, Sr., Memorial Scholarship, Eastern Virginia Medical School
1974

Health Professions Scholarship, Eastern Virginia Medical School, 1973

NIH Fellow, Biochemistry Department, University of Virginia, 1971-1972

Listed in Castle Connolly Medical Ltd., America's Top Doctors, 2001, 2002,
2003, 2004, 2008, 2009, 2010, 2011, 2012, 2013

Listed in Woodward/White, Inc., The Best Doctors in America.
Second, Third, and Fourth editions, 1994, 1996, 1998

Listed in Best Doctors, Inc. 2003, 2004, 2005, 2006, 2009

Listed in Texas Super Doctors (Texas Monthly magazine) 2006, 2008, 2009,
2010, 2011, 2012, 2013, 2014

EDITORIAL POSITIONS AND REVIEWER ACTIVITIES

Editorial Board, Scleroderma Care and Research, 2003, 2004, 2005

Annals of Internal Medicine, 1999, 2001, 2004

Annals of the Rheumatic Diseases, 1998, 2010, 2011, 2013

Arthritis and Rheumatism, 1995, 1997, 1998, 1999, 2000, 2001, 2002, 2003,
2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014

Arthritis Care and Research, 2005, 2006, 2009, 2010, 2011, 2012, 2013, 2014

Archives of Internal Medicine, 2004

Clinical and Experimental Rheumatology 2010, 2011, 2013

Journal of Clinical Investigation, 1998, 2000

Journal of Rheumatology, 2001, 2004, 2005, 2006, 2007, 2009, 2010, 2011,
2013, 2014

Nature Reviews Rheumatology 2014

Rheumatology Oxford 2010

Seminars in Arthritis & Rheumatism 2004

SERVICE ON NATIONAL GRANT REVIEW PANELS, STUDY SECTIONS, COMMITTEES

Ad hoc Reviewer, V.A. Grants Review Process, 1989, 1990, 1995

Ad hoc Grant Reviewer, NIH/National Institute of Environmental Health Sciences (NIEHS), 1996, 2000.

Ad hoc Grant Reviewer, NIH/National Institute of Arthritis, Muscular-Skeletal and Skin Diseases (NIAMS), 1998, 1999, 2000, 2003, 2004, 2005, 2006, 2008, 2009, 2011

Ad hoc Grant Reviewer, NIH/National Institute of Allergy and Infectious Diseases (NIAID), 2009

Member, Study Section, Scleroderma Foundation National Grant Review Committee, 1999, 2000, 2005, 2006, 2007, 2008

Ad hoc Grant Reviewer, NIH, National Institute of Dental and Craniofacial Diseases Special Emphasis Panel, 2005-2007

Member, NIH/NIAMS P30 RDCC Review Panel, 2005 and 2007

Chair, Special Emphasis Panel, NIH/NIAMS, 2006
Chair, Special Emphasis Panel, NIH/NIAID, 2009

Ad hoc Grant Reviewer, UK National Institute for Health Research (NHS), 2009

Ad hoc Grant Reviewer, NIH/NIAMS Grand Opportunity Award, 2009

Ad hoc Grant Reviewer, NIH/NIAMS Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Awards, 2010, 2011 (Chair in 2011)

Member, NIH/NIAMS P60 MCRC Review Panel, 2011-2012

Ad hoc Grant Reviewer, DOD Clinical Trials Review Panel 2013

2015 Ishmael Lectureship



Member, NIH/NIAMS Arthritis, Connective Tissue and Skin (ACTS) Study Section, 2013-2016

Member, NIH/NIAMS Special Review Panel, Accelerating Medical Partnerships (AMP), July 2014

SERVICE ON THE UNIVERSITY OF TEXAS-HOUSTON MEDICAL SCHOOL COMMITTEES

- | | |
|-----------|---|
| 2002-2003 | Chair, Evidence-Based Medicine Task Force for the Internal Medicine Residency Program |
| 2002-2007 | Member, Scientific Advisory Committee for the UCRC |
| 2004-2008 | Interviewer, Medical School Admissions Committee |
| 2007-2011 | Chair, Internal Scientific Advisory Committee for CCTS |
| 2011-2013 | Chair, Data Safety and Monitoring Committee for UT-Health Centruy Trial (Cardiology) |

SERVICE TO THE COMMUNITY

- | | |
|-----------|--|
| 1986-1996 | Director, United Scleroderma Foundation National Board of Directors |
| 1988-1989 | President, National Board of Directors, United Scleroderma Foundation |
| 1994-2001 | Chair, National Medical Advisory Board, United Scleroderma Foundation |
| 2002- | Member, National Medical Advisory Board, Scleroderma Foundation |
| 2004- | Member, Medical Advisory Board, Texas Bluebonnet Chapter of the Scleroderma Foundation |

CURRENT TEACHING RESPONSIBILITIES

Lecturer in 2nd year medical student Rheumatology small group case sessions
Participant weekly Rheumatology Journal Club, Case Conference and monthly Rheumatology Grand Rounds for the TMC
Rheumatology Consult and Teaching Rounds
Faculty, Center for Clinical Research and Evidence Based Medicine and course instructor for 4th year medical student clinical epidemiology course 2002-2003, and Fall 2003.

SPONSORSHIP OF POSTDOCTORAL FELLOWS

- a. Patricia Dhar, M.D., WSU postgraduate rheumatology fellow.
Project: The development of auto-immune disease in a large population of bone marrow transplant patients. Presented at American Rheumatism Association Meeting, Washington, DC, June 1987. *Arthritis Rheum* 30 (Suppl): S36, 1987.
- b. A.D. Mosley, M.D., WSU postgraduate rheumatology fellow.
Project: Long-standing alcohol abuse and chronic inflammatory polyarthritis. Presented at the MI. Chapter ACP Meeting, Grand Traverse Village, MI, September 1987.
- c. M.C. Haller, M.D., WSU postgraduate rheumatology fellow.
Winner of Central Region American Rheumatism Association Fellows Award, November 1988. Project: Effects of Interleukin-1 on collagenase activity of scleroderma cells in a collagen matrix. *Clin Res* 36:842a, 1988. Presented at Midwest AFCR Meeting, Chicago, IL, November 1988.
Clinical Project: Hemophilus influenza arthritis mimicking acute gonococcal arthritis. Case report and review of the literature. Presented at Michigan ACP Meeting, Traverse City, MI, 1988
- d. C.J. Huebner, M.D., WSU postgraduate rheumatology fellow.
Project: Polyarticular septic arthritis. Presented at Michigan ACP Meeting, Traverse City, MI, September 22, 1989; Project: Autoantibodies to collagen in scleroderma. Presented at Michigan ACP Meeting, Traverse City, MI, September 1990.
- e. Kathy Hajj, M.D., WSU postgraduate medicine resident.
Project: "Family studies in scleroderma," 1991.
- f. Christine Adamick, WSU first year medical student. Summer research laboratory project: I1-6 as a mediator of elevated TIMP and collagen synthesis in scleroderma fibroblasts, 1991.
- g. Mina Mark, M.D., WSU postgraduate rheumatology fellow.
Project: The role of I1-6 in Scleroderma, 1992-1993.
- h. Bassel Darwish, M.D., WSU postgraduate medical resident.
Clinical research project: Hyperlipidemia and increased risk of cardiovascular complications in scleroderma, 1995.
- i. Paul Gryzenia, WSU MS1. Clinical research project: Prevalence and incidence of scleroderma in Southeast Michigan, 1995.
- j. Farrukh Anwar, M.D., WSU Rheumatology fellow. Clinical research project: The natural history of systemic sclerosis with diffuse skin involvement. July 1, 1999, to December 15, 1999.

- k. Soumya Chatterjee, M.D., WSU Rheumatology fellow. Clinical research project: Epidemiological Features in Scleroderma. July 1, 2000, to June 30, 2001.
- l. Daniel P. O'Donnell, WSU MS I. Summer clinical preceptorship funded by the American College of Rheumatology, Summer, 2001. Project: Minocycline in Scleroderma.
- m. Carina Eastman, UT-H Summer Undergraduate Research Program. Clinical research project: Autoantibodies in Scleroderma Patients and their Family Members, Summer, 2002
- n. Josh Barron, UT-H Summer Undergraduate Research Program. Pedigrees of Multicase Autoimmune Disease Families, Summer, 2003.
- o. Shervin Assassi, MD, UT-H Rheumatology Fellow. Clinical research project: Characteristics of Scleroderma Multicase Families, 2003-2004.
- p. Jo Elle Peterson, UT-H medical student summer research project: Prevalence of positive autoantibodies in first degree relatives of SSC patients, 2004.
- q. Rachel Cohen, UT-H medical student summer research project: RNA-Polymerase III autoantibodies in Scleroderma Patients in the Scleroderma Registry, 2005.
- r. Megan MacNeil, MD, UT-H Rheumatology Fellow. Clinical research project: Damage Index in the GENISOS Cohort, 2006.
- s. Rajpreet Arora, MD, UT-H Medicine Resident. Laboratory research project: Association of PDGF gene polymorphisms in scleroderma, 2006.
- t. Firas Alkassab, MD, UT-H Rheumatology Fellow. Clinical research project: Pulmonary function test abnormalities in the GENISOS cohort, 2006.
- u. Kari Sutter, MD, UT-H Rheumatology Fellow. Clinical research project: Correlates of mortality in the GENISOS cohort, 2008.
- v. Tonya Cockrill, MD, UT-H Rheumatology Fellow. Clinical research project: Influence of birth order and parity on disease susceptibility in scleroderma, 2008.
- w. Rajpreet Arora, MD, UT-H Rheumatology Fellow. Clinical research project: Autoimmunity in first degree relatives of scleroderma patients.
- x. Binh Nguyen, MD, Rheumatology Fellow. Clinical research project: Predictors of poor outcome in Systemic Sclerosis, 2009.
- y. Gabriela Nicola, MD, UT-H Rheumatology Fellow. Clinical research project: Association of HLA with Pulmonary Arterial Hypertension. 2010.
- z. Mona Elhaj, MD, Rheumatology Fellow. Clinical research project: Association of HLA with Pulmonary Arterial Hypertension. 2011-2012.
- aa. Jammie Barnes, MD, Rheumatology Fellow. Clinical research project: Epidemiology of Systemic Sclerosis 2011-2012.
- bb. Gloria Salazar, MD, Rheumatology Fellow. Clinical research project: ANA negative systemic sclerosis 2012-2013.

- cc. Shervin Assassi, MD, Rheumatology Faculty; Mentor of K award 2011-2015
- dd. Joyce Joseph, MD, Rheumatology Fellow, Clinical research project: Rate of hand contracture formation in SSc.

CURRENT GRANT SUPPORT

- 2005 NIH/NIAID Subcontract from Duke University Medical Center. "A Randomized, Open-label, Phase II/III Multicenter Study of High-dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation with Auto-CD34+HPC versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis."
PI at UTHealth site
Period of Award: April 1, 2005 through Sept. 21, 2015
Total award \$828,158

- 2008 NIH/NHLBI Scleroderma Lung Study II: Multicenter study of Cyclophosphamide versus Mycophenylate Mofetil for the Treatment of Scleroderma Lung Disease
Principal Investigator: D. Tashkin, UCLA
Co-Investigator: MD Mayes (Principal Investigator at UT-Houston site)
Period of Award: October 1, 2008 through June 30, 2014
Total Award for UTHealth site: \$415,997

- 2008 NIH/NIAMS Two-Stage Genome-Wide Association Study in Systemic Sclerosis
Principal Investigator: MD Mayes
Period of Award: September, 2008 through June 2013, no cost extension through June 2015
Total Award for Project: \$6,040,109

- 2010 NIH/NIAID U01 The Architecture of the HLA Region in Systemic Sclerosis and Ankylosing Spondylitis. PI of Scleroderma Project
Period of Award: September 2010 through August 2015
Co-Principal Investigator at UTHealth site: MD Mayes
Total Award for Project: \$2,000,000

- 2012 DOD Cadherin-11 Regulation of Fibrosis through Modulation of Epithelial-to-Mesenchymal Transition: Implications for Pulmonary Fibrosis in Scleroderma
Period of Award: September 2012 – September 2015
Co-Investigator: MD Mayes

Total Award to UTHealth for Project: \$94,878

- 2012 Actelion Pharma Dual Studies: Digital Ulcers with Macitentan in Systemic Sclerosis
Period of Award: December 2011 – April 2014
Principal Investigator: MD Mayes
Total Award for Project: \$119,403
- 2012 Genentec/Roche A Phase II/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab versus Placebo in Patients with Systemic Sclerosis
Period of Award: January 2012 through January 2014
Co-Investigator at UTHealth: MD Mayes
Total Award for Project: \$99,687
- 2012 NIH/NIAMS Cadherin-11 Regulation of Dermal Fibrosis and Macrophage Function
Period of Award: September 2012 – August 2017
Principal Investigator: S. Agarwal at BCM
Co-Investigator at UTHealth: MD Mayes
Total Award for Project: \$30,573
- 2013 DOD: Predicting Disease Progression in Scleroderma with Skin and Blood Biomarkers
Period of Award: 9/23/2013 – 7/42/2016
Principal Investigator: MD Mayes
Total Award for Project: \$750,000
- 2013 Boehringer-Ingelheim Pharmaceuticals, Inc.: The Association Between Disease Specific Markers and Targets/Pathways Associated with Inflammation and Tissue Injury/Fibrosis in Systemic Sclerosis.
Period of Award: September 2013-August 2015.
Principal Investigator: MD Mayes
Total Award for Project: \$235,865
- 2013 InterMune, Inc.: PSSc-001: An Open-Label, Randomized, Phase 2 Study of the Safety and Tolerability of Pirfenidone when Administered to Patients with Systemic Sclerosis-Related Interstitial Lung Disease.
Period of Award: November 2013-October 2015.
Principal Investigator: MD Mayes
Total Award for Project: \$30,000

2012 NIH NIAID: ACE Protocol ASC01: A Randomized, Double-blind, Placebo-controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) in the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.
Period of Award: October 2012-
Principal Investigator: MD Mayes
Total Award for Project: per patient

PAST GRANT SUPPORT

1982 West Virginia University Biomedical Grant, "Lymphocyte Macrophage Interaction in Scleroderma," P.I. MD Mayes, \$4,900, 1982-1983

1983 United Scleroderma Foundation, "Immunocytochemical study of the Connective Tissue Matrix in PSS (Progressive Systemic Sclerosis)," P.I. MD Mayes, \$10,000, 1983-1984

1988 Michigan Chapter, Arthritis Foundation, "Regulation of Collagen Metabolism by Scleroderma Fibroblasts," \$9,231, P.I. MD Mayes, Period of award: January 1988-December 1989.

1989 Harper Hospital Medical Staff Trust Fund, "Study of Collagen Metabolism in a Collagen Matrix," \$30,484.P.I. MD Mayes. Period of award: January 1989-December 1989.

1989 Michigan Chapter Arthritis Foundation, continuation of "Regulation of Collagen Metabolism by Scleroderma Fibroblasts," \$10,000.P.I. MD Mayes. Period of award: January 1989-December 1989.

1989 Berlex Laboratories, "Study of Intravenous Iloprost in patients with Raynaud's Phenomenon Secondary to Scleroderma," \$67,959. Period of award: January 1989-December 1989.P.I. MD Mayes.

1989 Glenwood Laboratories, University of Utah subcontract, participating clinic, "Comparison of Potaba and Placebo in the treatment of Scleroderma," \$51,800. Period of award: June 1989-February 1990. P.I. MD Mayes.

1990 Glenwood Laboratories, extension of subcontract: March 1, 1990-February 28, 1991.

1991 Upjohn Company, "A Twelve Week Comparison of Ansaid Tablets

2015 Ishmael Lectureship



Arthritis
Foundation™



The UNIVERSITY of OKLAHOMA
Health Sciences Center

with Naprosyn Using Flexible Dosing Schedules for the Disease Management of Patients with Rheumatoid Arthritis," \$48,200. Period of award: January 1, 1991-December 31, 1991.P.I. MD Mayes.

- 1991 Dow-Corning Corp., "The Epidemiology of Scleroderma: A population-based case-control study." Co-Investigator, 5% salary. Period of award: July 1, 1991-June 30, 1996.
- 1992 Centocor, "Phase II Study of Chimeric Anti-CD4 in patients with Rheumatoid Arthritis on a Stable Regimen of Low Dose Methotrexate," \$94,891. Period of award: November 1, 1992-October 1, 1997.P.I. MD Mayes.
- 1993 Michigan Chapter Arthritis Foundation, "Interleukin 6 and Tissue Inhibitors of Metalloproteinases (TIMP-1 and TIMP-2) in Systemic Sclerosis," \$10,000.Principal Investigator. Period of award: January 1, 1993- December 31, 1993.P.I. MD Mayes.
- 1994 Michigan Chapter Arthritis Foundation, "Myofibroblasts in Scleroderma," \$10,000. Period of award: January 1994-December 1994. P.I. MD Mayes.
- 1994 NIH, National Research Service Award, Senior Fellowship Application (F-33), salary support of \$32,500, "Prevalence, Incidence and Mortality of Scleroderma in the Detroit Metropolitan Area." Period of award: January 1994-August 1994, to include course work for the M.P.H. degree at the School of Public Health, University of Michigan Department of Epidemiology.
- 1994 Connective Therapeutics, "Clinical Trial of Relaxin in Scleroderma," Principal Investigator at W.S.U. site, \$16,685. Period of award: December 1, 1994-November 30, 1995.
- 1994 NIAMS Contract "Scleroderma Research Registry," Principal Investigator, \$832,085.Period of award: October 5, 1994-October 4, 1999.
- 1995 Therakos, a division of Johnson & Johnson, "Photopheresis in Scleroderma,," Principal Investigator at W.S.U. site, \$573,576. Period of award: January 15, 1995-January 14, 1998.
- 1995 Berlex Laboratories, "Oral Iloprost for the Treatment of Raynaud's Phenomenon Secondary to Systemic Sclerosis," Principal Investigator at W.S.U. site, \$69,150. Period of award: December 1995-November 1996.

- 1996 Connective Therapeutics, "A Phase I Study of Subcutaneous Continuous Infusion of Recombinant Human Relaxin Manufactured by a Single Chain Process in Patients with Systemic Sclerosis with Diffuse Scleroderma," Principal Investigator at W.S.U. site, \$31,256. Period of Award: February 1996-January 1997.
- 1996 NIH, "Behavioral Treatment of Raynaud's Phenomenon," Co-Investigator (20% time for first 2 years, then 10% time), \$257,054 (total costs for entire period). Period of award: January 1, 1997-June 30, 2000.
- 1997 Glaxo Wellcome, "A Multicenter, Open-label, Randomized, Parallel Comparison of the Safety and Efficacy of Chronic FLOLAN Infusions to Conventional Therapy Alone in Patients with Isolated Pulmonary Hypertension Secondary to the Scleroderma Spectrum of Diseases: A Twelve-Week Study," Co-Investigator at W.S.U. site, \$200,011. Period of Award: January 1, 1997-December 1998.
- 1998 Connetics Corporation, "A Phase II/III Placebo-Controlled Safety and Efficacy Study of Recombinant Human Relaxin Therapy in Subjects with Systemic Sclerosis with Diffuse Scleroderma," Principal Investigator at W.S.U. site. Period of Award: February 1999-January 2002.
- 1999 NIH/NIAMS, one-year funded extension of Scleroderma Research Registry, Principal Investigator (30% time), \$170,578 (total costs for one-year extension). Period of award: 10/1/1999-9/30/2000.
- 1999 NIH/NHLBI, "Scleroderma Lung Study: Oral Cyclophosphamide vs. Oral Placebo in SSc Pulmonary Alveolitis," Co-Investigator 1999-2000, now Principal Investigator at UTH site (5% time), \$255,788. Period of Award: October 1, 1999-September 30, 2004, no cost extension to 9/05.
- 1999 NIH/NIAMS, "Multicenter Phase II Trial of Oral Type I Bovine Collagen in Scleroderma," Principal Investigator at UTH site (5% for first year, then 15%), \$201,282 (total costs at WSU then UTH site for entire period). Period of Award: October 1, 1999-September 30, 2004, no cost extension to 9/05.
- 2000 NIH/NIAMS, "Scleroderma Family Registry and DNA Repository," P.I. (20% time), \$4,400,234 total award. Period of Award: September 30, 2000 – September 29, 2005, no cost extension to September 29, 2006.

2015 Ishmael Lectureship



- 2001 Research and Education Foundation of the American College of Rheumatology Summer Medical Student Summer Clinical Fellowship Award, \$3,000 (Dr. Mayes as preceptor with Dr. Mosley-Williams).
- 2001 NIH/NIAMS, R21 "Study of Persistent Infections in SSc Skin and Vessels," P.I., (5% time) \$335,250. Period of award: September 30, 2001 - September 29, 2004, no cost extension to 9/06.
- 2003 Genzyme Corporation "A Phase I/Phase II Double-blind, Placebo Controlled, Randomized, Dose Ranging, Repeat Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of CAT-192 Human Anti-TGF- β 1 Monoclonal Antibody in Patients with Diffuse Systemic Sclerosis. Principal Investigator at UTH site. Total award \$47,620. Period of award: September 15, 2002 to September 15, 2003.
- 2003 NIH/NIAMS, Project 3 of Scleroderma SCOR "Genes versus Environment in Scleroderma Outcomes Study (GENISOS)," P.I. as of November 2003 (replacing Dr. John Reveille), 20% time and effort. Period of award: Sept. 1, 2001 to Aug. 31, 2006.
- 2003 Actelion Pharmaceuticals, Inc., BUILD 2 Study: Double-blind, placebo-controlled, multicenter study to assess the efficacy, safety and tolerability of Bosentan in patients with interstitial lung disease associated with systemic sclerosis. PI at UTH site. Total award \$170,000. Period of award: Aug. 1, 2003 to Jan. 1, 2006
- 2003 Minority Supplement award to the GENISOS project (noted above). Mentor for Dr. A. Robles, Pulmonary Medicine. Total award \$348,855. Period of award: September, 2003 to February, 2006 (truncated due to Dr. Robles leaving the institution).
- 2003 Actelion Pharmaceuticals, Inc., RAPIDS-2 Study: A Randomized, double blind, placebo-controlled, multi-center study to assess the effect of bosentan on healing and prevention of ischemic digital ulcers in patients with systemic sclerosis. PI at UTH site. Total award \$60,000. Period of award: October, 2003 to October, 2005.
- 2004 Genzyme Corporation: Clinical Screening Protocol to Characterize the Clinical Status of Patients with Diffuse Systemic Sclerosis for Inclusion in a Clinical Trial. PI at UTH site. Total award \$5,200. Period of award: January 2004 to October 2004.

2015 Ishmael Lectureship



- 2005 NIH/NIAID R34 Planning Grant for one year
Title: Allogeneic Transplantation for Severe Systemic Scleroderma
Proposed Period of Award: January 2006 through December 2006.
Principal Investigator: Richard Nash, Fred Hutchinson Cancer Center, Seattle. Co-Investigator: MD Mayes (Principal Investigator at UT-Houston site). Total Award for Project at UT-Houston: \$25,825. Period of award: July 2006 to June, 2007.
- 2005 Actelion Pharmaceuticals, Inc., RAPIDS-2 Open Label Extension Study: A multi-center open label study to assess long term safety and the effect of bosentan on healing and prevention of ischemic digital ulcers in patients with systemic sclerosis. PI at UTH site. Total award \$60,000. Period of award: October, 2005 to December, 2008
- 2006 DOD (Department of Defense): Candidate Gene Polymorphisms in Scleroderma: Defining Susceptibility Factors
Principal Investigator: MD Mayes
Period of Award: Feb 5, 2007 through Mar 4, 2011
Total Award for Project: \$928,125
- 2007 NIH/NIAID: Pregnancy, Microchimerism and Autoimmune Diseases (Fred Hutchinson Cancer Center) (R01)
Role of Dr. Mayes: consultant
Period of Award: 5/1/2007 – 4/30/2012
Total Award: \$6,661
- 2007 NIH/NIAMS: Provisional Combined Response Index for Patients with Diffuse Systemic sclerosis (U01)
Principal Investigator at UT-H site: MD Mayes (overall PI Daniel Furst at UCLA)
Period of Award 8/1/2007– 7/31/2010 with no cost extension to 7/31/2011
Total award: \$26,210
- 2009-2012 United Therapeutics Corp. DISTOL Study – Digital Ischemic Lesions in Scleroderma Treated with Oral Treprostinil Diethanolamine: A randomized, double-blind, placebo-controlled multicenter study
Period of Award: November 2009 through November 2012
Principal Investigator at UTHealth site: MD Mayes
Total Award for Project: \$68,900
- 2011 United Therapeutics Corp., Investigator Initiated Study of HLA Associations in Scleroderma-Related Pulmonary Arterial Hypertension

Period of Award: January 2011 through January 2013
Principal Investigator: MD Mayes
Total Award for Project: \$30,000

2012
Celgene: A Phase 2, Proof of Concept, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects with Diffuse Cutaneous Systemic Sclerosis with Interstitial Lung Disease
Period of Award: April 2012 – June 2013
Principal Investigator: MD Mayes
Total Award for Project: \$112,511

2006
NIH/NIAMS P50 CORT (Center of Research Translation)
PI of Project 2: Gene Expression as Predictors of Outcome in the GENISOS (Genes versus Environment in Scleroderma Outcome Study) Cohort
Program Project Director: FC Arnett until 8/30/2010; MD Mayes 9/1/2010
Period of Award: September 2006 through August 2011, no cost extension through August 2013
Total Award for Project: \$9.8 million

PUBLICATIONS

A. PUBLISHED ABSTRACTS (since 1996):

1. Clements P, Furst D, Mayes M, McCloskey D, Moreland L, White B, Wigley F, Rocco S, Mangan C, Erickson M, Sanders M, and Amento E. Safety and Pharmacokinetics of Recombinant Human Relaxin in Scleroderma (SSc). *ArthritisRheum* 39 (Suppl): S152, 1996.
2. Mayes M, Laing T, Gillespie B, Cooper B, Lacey Jr. J, Hirschenberger W, Atty S, and Schottenfeld D. Prevalence, incidence and survival rates of systemic sclerosis in the Detroit Metropolitan Area. *Arthritis Rheum* 39 (Suppl): S150, 1996.
3. Laing T, Gillespie B, Lacey Jr. J, Garabrant D, Cooper B, Heeringa S, Alcser K, Sungwon C, Mayes M, and Schottenfeld D. The association between silicone exposure and undifferentiated connective tissue disease among women in Michigan and Ohio. *Arthritis Rheum* 39 (Suppl): S150, 1996.
4. Seibold JR, McCloskey DA, Clements PJ, Mayes MD, Rocco SE, Harkonen WS, and Sanders ME. Six month pilot trial of recombinant human relaxin (rhRlx) in diffuse scleroderma. *Brit J of Rheumatol* 36 (Suppl 1): 29, 1997.
5. Lacey Jr. JV, Garabrant DH, Gillespie BW, Cooper BC, Laing TJ, Mayes MD, and Schottenfeld D. Self-reported exposure to solvents in women with systemic sclerosis (SSc). *Arthritis Rheum* 40 (Suppl): S201, 1997.

6. Beebe JL, Lacey Jr. JV, Mayes MD, Gillespie BW, Cooper BC, Laing TJ, and Schottenfeld D. Reproductive history, oral contraceptive use, estrogen replacement therapy and the risk of developing scleroderma. *Arthritis Rheum* 40 (Suppl): S100, 1997.
7. Lacey Jr. JV, Garabrant DH, Gillespie BW, Cooper BC, Laing TJ, Mayes MD, and Schottenfeld D. Self-reported exposure to solvents in women with undifferentiated connective tissue disease (UCTD). *Arthritis Rheum* 40 (Suppl): S201, 1997.
8. Lacey Jr. JV, Beebe JL, Mayes MD, Gillespie BW, Laing TJ, Cooper BC, and Schottenfeld D. Reproductive history, oral contraceptive use, and estrogen replacement therapy in women with undifferentiated connective tissue disease (UCTD). *Arthritis Rheum* 40 (Suppl): S119, 1997.
9. Korn J, Simms R, Clements PJ, Moreland L, Mayes MD, Furst DE, Rothfield N, Steen V, Weisman M, DeMarco P, Collier D, Wigley F, Merkel PA, Csuka ME, Rocco S, Erikson M, Hannigan J, Harkonen WS, and Sanders ME. Controlled trial of recombinant human relaxin (rhRlxn) in diffuse scleroderma (DS). *Arthritis Rheum* 40 (Suppl): S123, 1997.
10. Clements PJ, Wong WK, Seibold JR, Furst DE, Mayes M, White B, Wigley F, Weisman M, Barr W, Weinstein A, Medsger Jr. T, Steen V, Martin R, Moreland L, Collier D, Lally E, Varga J, Andrews B, Weiner S, and Abeles M. High-dose (HI-DPA) vs low-dose (LO-DPA) penicillamine in early diffuse systemic sclerosis (SSc) trial: analysis of trial. *Arthritis Rheum* 40 (Suppl): S173, 1997.
11. Kirk TZ, and Mayes MD. Abnormal apoptosis in scleroderma myofibroblasts. Abstract presented at the International Scleroderma Conference, Montecatini Terme, Italy, March, 1998. *Clin Exp Rheum* 16(3): 367, 1998.
12. Doss B, Jacques SM, Atty S, Mayes MD, and Qureshi F. Maternal scleroderma: placental findings and perinatal outcome. *Human Pathology* 28:1524-1530, 1998.
13. DeMarco PJ, Weisman M, Wong WK, Clements PJ, and the High Dose vs Low Dose Penicillamine in SSc Trial Investigators. Predictors and outcome of scleroderma renal crisis in an early disease (<18 months) cohort of patients followed for 4 years. *Arthritis Rheum* 41 (Supp): S239, 1998.
14. Injic Z, and Mayes MD. The use of indwelling venous catheters in patients with systemic sclerosis (SSc). *Arthritis Rheum* 41 (Supp): S9183, 1998.
15. Lacey Jr. JV, Mayes MD, Laing TJ, Gillespie BW, Garabrant DH, and Schottenfeld D. Self-reported medical history and medication use among women with undifferentiated connective tissue disease. *Arthritis Rheum* 41 (Supp): S336, 1998.
16. Lacey Jr. JV, Garabrant DH, Mayes MD, Laing TJ, Gillespie BW, and Schottenfeld D. Self-reported exposure to pesticides and herbicides as risk factors for undifferentiated connective tissue disease (UCTD). *Arthritis Rheum* 41 (Supp): S336, 1998.

17. Herlyn K, Martin RW, Schoenfeld DA, Merkel PA, and Scleroderma Clinical Trials Consortium. Association between climatic factors and severity of Raynaud's Phenomenon in patients with systemic sclerosis. *Arthritis Rheum* 41 (Supp): S216, 1998.
18. Aguilar MB, Cho M, Reveille JD, Mayes MD, and Arnett FC. Prevalence of familial systemic sclerosis and other autoimmune diseases in three U.S. cohorts. *Arthritis Rheum* (Supp): S186, 1999.
19. Nash RA, Dansey R, Storek J, Sullivan KM, Pavletic S, McDonagh KT, Kraft GH, Mayes MD, Forman SJ, Holmberg LA, and McSweeney PA. Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD) after high-dose immunosuppressive therapy (HDIT) and autologous CD34-selected stem cell transplantation (SCT) for severe autoimmune diseases. *American Society of Hematology*, 2000.
20. Chatterjee S, Severson RK, Weiss LK, Kau T-Y, and Mayes MD. Risk of Malignancy in Scleroderma. *Arthritis Rheum* 43 (Supp): S315, 2000.
21. Furst DE, McSweeney P, Nash R, Holmberg I, Viganego F, Nelson L, Wener M, McDonagh K, Crofford L, Storek J, Agee G, Ryan K, Prather K, Mayes M, Dansey R, and Sullivan K. High-dose immunosuppressive therapy (HDIT) with autologous stem cell transplantation (SCT) for systemic sclerosis (SSc): results in the first 8 patients. *Arthritis Rheum* 43 (Supp): S392, 2000.
22. Seibold JR, Clements PJ, Korn JH, Ellman M, Rothfield NF, Wigley FM, Moreland LW, Kim Y, Silver RM, Furst DE, Steen VD, Firestein GS, Kavanaugh AF, Mayes MD, Collier D, Csuka ME, Simms R, Merkel P, Medsger TA, Erikson M, Rocco S, Hannigan J, Sanders ME. US. Phase III Trial of Relaxin in Diffuse Scleroderma. Presented at the ILAR (International League against Rheumatism) meeting, Edmonton, Canada, August, 2001.
23. Furst DE, McSweeney P, Nash R, Storek J, Crofford LJ, McDonagh KT, Mayes M, Dansey RD, Colburn KK, Chen C-S, Sullivan KM. One year outcome of autologous stem cell transplantation (SCT) in 19 patients with severe SSc. *Arthritis Rheum* 46 (Supp): S267, 2001.
24. Mayes MD, O'Donnell D, Csuka ME, Rothfield NF. Multicenter, open-label trial of minocycline in early diffuse SSc. *Arthritis Rheum* 47 (Supp): S357, 2002.
25. Black C, Korn J, Mayes M, Rainisio M, Gaitonde M, Nguyen N, on behalf of the RAPIDS-1 Study Group. An exploratory, double-blind, randomized, placebo-controlled study on the prevention of ischemic digital ulcers secondary to systemic sclerosis. Late-breaking abstract, American College of Rheumatology annual meeting, New Orleans, LA, October, 2002.
26. Assassi S, Tercero GM, Reveille JD, Arnett FC, Mayes MD, McNearney T, Fischbach M, Tan, FK. Polymorphisms of the endothelial nitric oxide synthase and angiotensin conversion enzyme show no association with systemic sclerosis. *Arthritis Rheum* 48 (Supp): S159, 2003.

27. Mayes MD, Lee J, Luo J, Li J, Tan FD, Arnett FC, Tan FK. Candidate gene regions associated with systemic sclerosis (SSc): A family-based association study using TDT analysis. *Arthritis Rheum* 48 (Supp): S227, 2003.
28. Black CM, Korn JH, Mayes MD, Matucci-Cerinic M, for the RAPIDS-1 Study Group. Improvements in the net ulcer burden and hand functionality in patients with digital ulcers related to systemic sclerosis. *Arthritis Rheum* 48 (Supp): S454, 2003.
29. Furst DE, Nash RA, McSweeney P, Storek J, Georges E, Holmberg LA, Kraft GH, Mayes MD, McDonagh K, DiPersio J, LeMaistre F, Chen CS, Pavletic S, Sullivan K, Sunderhaus J, Dansey R. Intensive immunosuppression, particularly using higher dose rabbit ATG, may predispose to post transplantation lymphoproliferative disease (PTLD) in patients undergoing high dose immunosuppression with stem cell transplantation (SCT). *Arthritis Rheum* 48 (Supp): S626, 2003.
30. Clements PH, Khanna D, Furst DE, Sterz M, Chon Y, Lin R, Tashkin D, Elashoff R for the Scleroderma Lung Study Investigators. The degree of dyspnea correlates with health related quality of life (HRQOL), functional abilities, patient global assessment, forced vital capacity (%FVC) and diffusing capacity (%DLCO) in systemic sclerosis (SSc) patients with active alveolitis. *Arthritis Rheum* 48 (Supp): S558, 2003.
31. Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Seibold JR, for the Relaxin Study Group. Responsiveness of the health related quality of life (HRQOL) instruments (SF 36 and HAQ-DI) in a systemic sclerosis (SSc) clinical trial. *Arthritis Rheum* 48 (Supp): S398, 2003.
32. Mayes MD, Zhang G, Luo J, Jin L, Tan FK, Arnett FC. Candidate genes associated with systemic sclerosis (SSc): A family-based genetic association study using 116 SNP's. *Arthritis Rheum* 50 (Supp): S622, 2004.
33. Tan FK, Hildebrand BA, Lester MS, Wallis D, Milewicz DM, Zhou X, Mayes MD, Arnett, FC. Classification analysis of the transcriptome of dermal fibroblasts from systemic sclerosis (SSc) patients. *Arthritis Rheum* 50 (Supp): S621, 2004.
34. McSweeney PA, Furst DE, Crofford LJ, McDonagh KT, Sullivan KM, Mayes MD, Nelson JL, Gooley TA, Holmberg LA, Chen CS, Wener MH, Lee J, Henstorf G, Abidi M, Nash RA. High-Dose Immunosuppressive Therapy for Severe Systemic Sclerosis: Long-term follow-up demonstrates continued improvement in function and skin with stability in the lungs. *Blood* 104:46a (abstract), 2004.
35. Suarez-Almazor M, Blanco A, Reveille JD, Mayes M. Disease and symptom burden in systemic sclerosis: the patients' perspective. *Arthritis Rheum* 50 (Supp): S423, 2004.
36. Wigley FM, Mayes MD, Lima JAC, McLain DA, Chapin L, Ward-Able C. The point prevalence of undiagnosed pulmonary hypertension (PAH) in patients with connective tissue disease (CTD) attending community based rheumatology clinics (UNCOVER Study). *Arthritis Rheum* 50 (Supp): S424, 2004.
37. Furst DE, McSweeney PA, Crofford LJ, McDonagh KT, Sullivan KM, Mayes MD, Nelson JL, Gooley TA, Holmberg LA, Chen CS, Wener MH, Lee J, Henstorf G,

- Abidi M, Nash RA. High-Dose Immunosuppressive Therapy (HDIT) for SSc: Results of 3 year follow-up demonstrates continued improvement in function and skin with stability in the lungs. *Arthritis Rheum* 50 (Supp): S693, 2004.
38. Mayes MD, Zhang G, Luo L, Jin L, Tan FK, Arnett FC. Polymorphisms in the ESRRG (Estrogen Receptor Related Gamma) gene are associated with Systemic Sclerosis (SSc). *Arthritis Rheum* 52 (Supp) S365:2005.
39. Mayes MD, Ahn C, Arnett FC, Reveille JD. HLA Class II Associations in Systemic Sclerosis (SSc) from the Scleroderma Family Registry and DNA Repository. *Arthritis Rheum* 52 (Supp) S582:2005.
40. Peterson JEG, Perry MF, Arnett FCA, Mayes MD. Antinuclear Antibodies and non-SSc Autoimmune Diseases in First-degree Relatives of Scleroderma Patients: Data from the Scleroderma Family Registry and DNA Repository. *Arthritis Rheum* 52 (Supp) S583:2005.
41. Gardner HAR, Trojanowska M, Smith E, Pannu J, Shearstone J, Bandaru R, Tan FK, Mayes MD. Intact scleroderma biopsies have a strong transcript profile fingerprint which is incompletely reflected by explant fibroblast cultures. *Arthritis Rheum* 52 (Supp) S462:2005.
42. Gourh P, Assassi S, Watson K, Mayes MD, Tan F, Arnett FC. Association of Functional PTPN22 1858 C→T Polymorphism with Systemic Sclerosis. *Arthritis Rheum* 52 (Supp) S369:2005.
43. McNearney TA, Fischbach M, Reveille JDR, Goel N, Lisse JR, Ahn C, Arnett FC, Feghali C, Mayes MD. Early pulmonary involvement in systemic sclerosis: Associations with genetic, serologic, sociodemographic, and behavioral factors in the GENISOS cohort. *Arthritis Rheum* 52 (Supp) S172:2005.
44. Merkel PA, Silliman NP, Clements PJ, Denton CP, Furst DE, Mayes MD, Pope JE, Polisson RP, Streisand JB, Seibold JR for the Scleroderma Clinical Trials Consortium (SCTC). Performance of the Modified Rodnan Skin Score in clinical trials of scleroderma. *Arthritis Rheum* 52 (Supp) S283:2005.
45. Merkel PA, Silliman NP, Clements PJ, Denton CP, Furst DE, Mayes MD, Pope JE, Polisson RP, Streisand JB, Seibold JR for the Scleroderma Clinical Trials Consortium (SCTC). Patterns and predictors of change in outcome measures in clinical trials in scleroderma. *Arthritis Rheum* 52 (Supp) S282:2005.
46. MacNeil MC, Ahn CW, McNearney T, Fischbach M, Feghali-Bostwick C, Fritzler M, Reveille JD, Arnett FC, Mayes MD. Application of the scleroderma disease severity scale to a multiethnic prospective early disease cohort: Data from the GENISOS (Genes versus Environment in Scleroderma Outcome Study) cohort. *Arthritis Rheum* 52 (Supp) S171: 2005.
47. Tan F, Zhou X, Mayes MD, Marcum C, Gio X, Gourh P, Jin L, Arnett Jr, FC. Gene expression signatures of vasculotropism in peripheral blood cells from patients with early systemic sclerosis. *Arthritis Rheum* 52 (Supp) S366: 2005.

48. Seibold JR, Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Kramer F, Morganti A, Korn JH. Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis. *EULAR* 2006.
49. Gourh P, Tan FK, Mayes MD, Arnett FC. Association of functional TYK2 V362F polymorphism with systemic sclerosis. *Arthritis Rheum* 54 (Supp) L17:2006.
50. Arora-Singh RK, Gourh P, Tan F, Perry M, Mayes MD. PDGF gene polymorphisms are associated with scleroderma in Caucasians for the scleroderma Registry. *Arthritis Rheum* 54 (Supp) L18:2006.
51. Alkassab F, Arnett FC, Reveille JD, Ahn C, McNearney TA, Fischbach M, Estrada-y-Martin R, Feghali-Bostwick C, Fritzler M, Williams L, Mayes MD. Persistence of pulmonary function tests (PFTs) abnormalities in African American systemic sclerosis (SSc) patients compared to Caucasian and Hispanic patients in the GENISOS cohort. *Arthritis Rheum* 54 (Supp) F60:2006.
52. Nash RA, McSweeney PA, Crofford JL, McDonagh KT, Sullivan KM, Mayes M, Nelson JL, Gooley T, Holmberg L, Shulman H, Wener M, McLaughlin B, Henstorf G, Molitor J, Seibold JR, Furst DE. 5-year follow-up of high-dose immunosuppressive therapy (HDIT) for systemic sclerosis (SSc). *Arthritis Rheum* 54 (Supp) S315:2006.
53. Suarez-Almazor ME, Kriseman JL, Kallen MA, Mayes MD. Impact of illness and symptom burden in patients with systemic sclerosis. *Arthritis Rheum* 54 (Supp) S484:2006.
54. Assassi S, Arnett FC, Reveille JD, Gourh P, Tan FK, Mayes MD. Disease features, disease type HLA types and autoantibody profile in 17 multicase SSc families. *Arthritis Rheum* 54 (Supp) S485:2006.
55. Alkassab F, Gourh P, Tan FK, McNearney TA, Fischbach M, Ahn C, Arnett FC, Mayes MD. An allograft inflammatory factor 1 (AIF1) single nucleotide polymorphism (SNP) is associated with anticentromere antibody positive systemic sclerosis. *Arthritis Rheum* 54 (Supp) S732:2006.
56. Pope JE, Black C, Matucci-Cerinic M, Denton CP, Furst DE, Korn JH, Mayes MD, Morganti A, Seibold JR. Functional correlates of reduction of digital ulcers by bosentan therapy in patients with systemic sclerosis (SSc). *Arthritis Rheum* 54 (Supp) S740:2006.
57. Arora-Singh RK, Gourh P, Mayes MD, Arnett FC, Tan FK. Association of T-box transcription factor T-bet (TBX21) Polymorphism with Systemic Sclerosis, presented at the International Workshop on Systemic Sclerosis: Gene Polymorphisms, Clinical Variant and Response to Therapy, Milan Italy, 3/7 to 3/10/2007.
58. Arora-Singh RK, Gourh P, Divecha D, Arnett FC, Tan FK, Mayes MD. Association of Topoisomerase 1 Gene Polymorphisms with Systemic Sclerosis from the Scleroderma Registry. (Fellow abstract) (657) F119 *Arthritis Rheum* 56:4302: 2007.

59. Sutter K, Gourh P, Mayes MD, Arnett FC, Tan FK. Association of IL2RA Polymorphisms with Limited Systemic Sclerosis. (Fellow abstract) (659) F121 Arthritis Rheum 56:4304:2007.
60. Sule SD, Hummers L, Shapiro L, Fiorentino D, Chung L, Baron M, Shanahan J, Hsu V, Rothfield N, Steen V, Martin R, Dugowson C, Smith E, Mayes M, Simms R, Pope J, Kahaleh B, Csuka ME, Gruber B, Collier D, Sweiss N, Klaff L, Dechow FJ, Gregory J, Wigley FM. Safety and Tolerability of MQX-503, a Novel Investigational Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon. Arthritis Rheum 56 (Supp): S62, 2007.
61. Gourh P, Arnett FC, Shete S, Mayes MD, Tan FK. Gene-Gene Interactions Mediating Susceptibility to Scleroderma: Investigation of A 3 Gene Network. Arthritis Rheum 56 (Supp): S66, 2007.
62. Gourh P, Zhou X, Assassi S, Arnett FC, Tan FK. Comparative Analysis of Dermal Fibroblast Gene Expression Profiles from Patients with Systemic Sclerosis and Hypertrophic Burn Scars. Arthritis Rheum 56 (Supp): S66, 2007.
64. Assassi S, Mayes MD, Gourh P, Arnett FC, Reveille JD, Poage C, McNearney T, Fischbach M, Tan FK. Systemic Sclerosis and Systemic Lupus Erythematosus have Distinct Gene Expression Profiles in the Peripheral Blood Cells. Arthritis Rheum 56 (Supp): S67, 2007.
65. Alkassab F, Ruchdi KB, Verani RR, Mayes MD, Dosekun AK. Lupus Nephritis in Patients with Longstanding Limited Scleroderma: A Report of Two Patients. Arthritis Rheum 56 (Supp): S489, 2007.
66. Schiopu E, Hsu V, Hummers L, Shapiro LS, Mayes MD, Csuka ME, Derk CT, Chung LS, Varga J, Furst DE, Silver RM, Wigley FM, Seibold JR, Steen VD. Pulmonary Hypertension (PH)-Assessment and Recognition of Outcomes in Scleroderma (Systemic Sclerosis, SSc): PHAROS. Arthritis Rheum 56 (Supp): S489, 2007.
67. Khanna D, Lovell DE, Giannini E, Clements PJ, Merkel PA, Seibold JR, Matucci-Cerinic M, Denton CP, Mayes MD, Steen VD, Varga J, Furst DE. Development of a Provisional Core Set of Response Measures for Clinical Trials of Systemic Sclerosis. Arthritis Rheum 56 (Supp): S823, 2007.
68. Chung L, Baron M, Collier D, Csuka ME, Fiorentino D, Gruber B, Hsu V, Kahaleh B, Martin R, Mayes MD, Pope J, Rothfield N, Shanahan J, Shapiro L, Simms R, Smith E, Steen V, Sule S, Sweiss N, Matthews E, Gilbert A, Dechow FJ, Wigley FM. A Multi-Center Placebo-Controlled "In-Life" Study of MQX-503 in Patients with Raynaud Phenomenon. Arthritis Rheum 56 (Supp): S824, 2007.
69. Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S, Hsu V, Rothfield N, Steen V, Martin R, Smith E, Mayes M, Simms R, Pope J, Kahaleh B, Csuka ME, Gruber B, Collier D, Sweiss N, Matthews E, Gilbert A, Dechow FJ, Wigley FM. MQX-503, A Novel Topical Nitroglycerin Formulation, Improves Severity of Raynaud Phenomenon in a Heterogeneous Patient Population. Arthritis Rheum 56 (Supp): S825, 2007.

70. Cockrill T, del Junco D, Arnett FC, Assassi S, Tan FK, Perry M, Mayes MD. Influence of Birth Order, Gravity and Parity on the Development of Systemic Sclerosis. *Arthritis Rheum* 58(12):4004, 2008 (Abstract F72).
71. Arora-Singh RK, Assassi S, del Junco D, Arnett FC, Irfan U, Perry M, Mayes MD. Autoimmune Disease Aggregation in families with systemic sclerosis from the Scleroderma Registry. *Arthritis* 58(12):3997, 2008 (Abstract F53).
72. Gourh P, Tan FK, Agarwal SK, Assassi S, Mayes MD, Arnett FC. Association of IL1A promoter polymorphism with systemic sclerosis. *Arthritis Rheum* 58(9) Supp:S589, 2008 (Abstract).
73. Gourh P, Assassi S, Agarwal SK, Mayes MD, Arnett FC, Tan FK. Association of FCRL3 promoter polymorphism with systemic sclerosis. *Arthritis Rheum* 58(9) Supp:S589, 2008 (Abstract).
74. Mayes MD, Gourh P, Assassi S, Tan FK, Charles J, Perry M, Arnett FC. Association of an estrogen-related receptor gamma (ESRRG) polymorphism with systemic sclerosis. *Arthritis Rheum* 58(9) Supp:S593, 2008 (Abstract).
75. Agarwal SK, Gourh P, Assassi S, Tan FK, Mayes MD, Arnett FC. Plasma cytokine profiles in autoantibody subsets of scleroderma. *Arthritis Rheum* 58(9) Supp:S836, 2008 (Abstract).
76. Gourh P, Tan FK, Agarwal SK, Assassi S, Arora RK, Mayes MD, Arnett FC. Association of T-box transcription factor T-bet (TBX21) polymorphism with Systemic sclerosis. *Arthritis Rheum* 58(9) Supp:S926, 2008 (abstract).
77. Fischer A, Impens A, Hsu V, Shapiro L, Mayes M, Hummers L, Csuka ME, Chung L, Hinchcliff M, Varga J, Derk C, Seibold J, Steen V. "PHAROS" Pulmonary Hypertension (PH) Assessment and Recognition of Outcomes in Systemic Sclerosis (SSc): Pre-Pulmonary Arterial Hypertension (PAH) Preliminary Outcomes. *Arthritis Rheum* 58(9) Supp:S377, 2008 (abstract).
78. Mayes MD, Keyes-Elstein L, Crofford LJ, Csuka ME, Furst DE, Goldmuntz E, McSweeney P, Nash R, Wallace D, Sullivan K, the SCOT Trial Investigators. Gastric Antral Vascular Ectasia (GAVE) in Early Diffuse SSc: Report from the SCOT Trial. *Arthritis Rheum* 58(9) Supp:S378, 2008 (abstract).
79. Assassi A, Mayes MD, Arnett FC, Gourh P, Agarwal SK, Reveille JD, Fischbach M, McNearney T, Tan FK. Peripheral Blood Cell (PBC) Gene Expression Profiles of Systemic Sclerosis and its Serological Subtypes. *Arthritis Rheum* 58(9) Supp:S590, 2008 (abstract).
80. Hsu V, Shapiro L, Fiorentino D, Rothfield N, Steen V, Martin R, Smith E, Sule S, Csuka ME, Mayes M, Kahaleh B, Gruber B, Simms R, Sweiss N, Dechow FJ, Gregory JK, Wigley FM. Phase III Open-Label Study of Topical Nitroglycerin, MQX-503, in the Treatment and Prevention of Raynaud's Phenomenon. *Arthritis Rheum* 58(9) Supp:S820, 2008 (abstract).
81. Rothfield N, Shapiro L, Fiorentino D, Chung L, Denton C, Herrick A, Baron M, Shanahan J, Hsu V, Belch J, Steen V, Scheja A, Martin R, Smith E, Mayes M, Simms R, Pope J, Kahaleh B, Csuka ME, Gruber B, Collier D, Sweiss N, Sule S, Emery P,

- Wigley FM. Safety and Tolerability of MQX-503, a Novel Investigational Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon. *Arthritis Rheum* 58(9) Supp:S821, 2008 (abstract).
82. McNearney T, Sallam H, Doshi D, Mayes MD, Chen JDZ. Neuro-Gastric Interactions: Prolonged Transcutaneous Electrical Nerve Stimulation (TENS) Treatment Demonstrated Improved Gastric Functioning by Electrogastrography, Pain Scores, Plasma VIP and IL-6 Levels in Systemic Sclerosis (SSc) Patients. *Arthritis Rheum* 58(9) Supp:S824, 2008 (abstract).
83. Assassi S, Fritzler MJ, Arnett FC, Norman G, Shah K, Gourh P, Manik N, Perry M, Rahbar MH, Mayes MD. Frequencies of Primary Biliary Cirrhosis (PBC), PBC Autoantibodies, and Liver Function Abnormalities In a Large Population of Systemic Sclerosis Patients. *Arthritis Rheum* 58(9) Supp:S947, 2008 (abstract).
84. Assassi S, Tan FK, McNearney TA, Estrada-Y-Martin R, Draeger HT, Anderson J, Arnett FC, Mayes MD. The Whole Blood Interferon Score Predicts Progression of Interstitial Lung Disease in Systemic Sclerosis. *Arthritis Rheum* 60(10) Supp: S164, 2009 (abstract).
85. Gorlova O, Weng SF, Ying J, Wigley FM, Hummers LK, Gregersen PK, Lee AT, Amos C, Arnett FC, Assassi S, Gourh PR, Tan FK, Reveille JD, Nelson JL, McNearney TA, Fischbach M, Mayes M. Genome-Wide Association Study of Systemic Sclerosis in a Large Cohort of Over 1,500 Cases. *Arthritis Rheum* 60(10) Supp: S203, 2009 (abstract).
86. Zhou X, Lee JE, Arnett FC, Xiong M, Park MY, You YK, Shin ES, Reveille JD, Mayes M, Kim JH, Song R, Choi JY, Park JA, Lee YJ, Lee EY, Song Y, Lee EB. HLA-DPB1 and DPB2 Are Genetic Loci for Systemic Sclerosis -Genome-Wide Association Study in Koreans with Replication in North Americans. *Arthritis Rheum* 60(10) Supp: S674, 2009 (abstract).
87. Broen JCA, Gourh PR, Rueda B, Hesselstrand R, Herrick AL, Worthington J, Agarwal SK, Tan FK, Denton CP, Fonseca J, Riemekasten G, Vonk MC, Hoogen FVD, Kiener H, Scorza R, Beretta L, Simeon C, Trapiella L, Callejas-Rubio JL, Fonollosa V, García-Hernández FJ, Pros A, Camps M, Gonzalez-Gay MA, Airo P, Coenen M, Mayes M, Martin J, Arnett FC, Radstake T. The FAS -670A>G Polymorphism Influences the Susceptibility to Systemic Sclerosis Phenotypes. *Arthritis Rheum* 60(10) Supp: S676, 2009 (abstract).
88. de Achaval S, Kallen M, Cox V, Mayes M, Suarez-Almazor ME, HRQoL Domain Coverage of the Patient Generated Index in Patients with Systemic Sclerosis: An Application of the PROMIS Framework. *Arthritis Rheum* 60(10) Supp: S29, 2009 (abstract).
89. Khanna D, Hays R, Maranian P, Seibold JR, Impens AJ, Mayes M, Clements PJ, Fathi N, Furst DE. Reliability, Validity, and Minimally Important Differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC 2.0) Instrument. *Arthritis Rheum* 60(10) Supp: S225, 2009 (abstract).

2015

Ishmael
Lectureship



Arthritis
Foundation™



The UNIVERSITY of OKLAHOMA
Health Sciences Center

90. Hsu VM, Khan H, Wu Y, Schiopu E, Mayes M, Derk CT, Shapiro LS, Csuka ME, Aryeh F, Khanna D, Domsic RT, Molitor JA, Steen VD, and the PHAROS Investigators. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): Two-Year Outcomes for Pre-Pulmonary Arterial Hypertension (PAH) *Arthritis Rheum* 60(10) Supp: S449, 2009 (abstract).
91. Impens AJ, Hinchcliff ME, Hummers LK, Mayes M, Derk CT, Shapiro LS, Domsic RT, Segal BM, Goldberg AZ, Alkassab F, Steen VD and the PHAROS Investigators. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): Utility of Six Minute Walk Test. *Arthritis Rheum* 60(10) Supp: S650, 2009 (abstract).
92. Chaudhary P, Chen X, Assassi S, Gorlova O, Draeger H, Gonzalez E, McNearney T, Perry M, Anderson J, Mayes M. Cigarette Smoking is Not a Risk Factor for Systemic Sclerosis. *Arthritis Rheum* 61(11), Supp: S234, 2010(abstract).
93. Hinchcliff ME, Fischer A, Sweiss N, Mayes M, Bolster M, Steen V, and the PHAROS Investigators. Scleroderma Autoantibodies and Disease Subtype Predict Pulmonary Hypertension Classification in the PHAROS Registry. *Arthritis Rheum* 61(11), Supp: S247, 2010 (abstract).
94. Wu M, Brenner MB, Mayes MD, Arnett FC, Tan FK, Agarwal SK. Cadherin-11 Systemic Sclerosis and Its Role in Dermal Fibrosis. *Arthritis Rheum* 61(11), Supp: S252, 2010 (abstract).
95. Wu M, Schneider DJ, Mayes MD, Assassi S, Arnett FC, Tan FK, Blackburn MR, Agarwal SK. Osteopontin in Systemic Sclerosis and Its Role in Dermal Fibrosis. *Arthritis Rheum* 61(11), Supp: S255, 2010 (abstract).
96. Nguyen BY, Mayes MD, Arnett FC, del Junco DJ, Gonzalez EB, Draeger HT, Perry M, Hendiani A, Reveille JD, Assassi S. HLA DRB1*0407 and *1304 Are Predictive Biomarkers for Scleroderma Renal Crisis. *Arthritis Rheum* 61(11), Supp: S302, 2010 (abstract).
97. Hung E, Mayes MD, Keyes-Elstein L, Crofford LJ, Csuka ME, Furst DE, Goldmuntz E, McSweeney P, Nash R, Machicao V and Sullivan K for the SCOT Trial Investigators. GAVE (Gastric Antral Vascular Ectasia) in Early Diffuse SSc: Updated Report from the SCOT (Scleroderma Cyclophosphamide or Transplant) Trial. *Arthritis Rheum* 61(11), Supp: S303, 2010 (abstract).
98. Diaz-Gallo LM, Gourh P, Broen J, Simeon C, Fonosolla V, Ortega-Centeno N, Mayes MD, Tan FK, Agarwal SK, Assassi S, Arnett FC, Reveille JD, et al. Analysis of the Influence of PTPN22 Gene Polymorphisms in Systemic Sclerosis. *Arthritis Rheum* 61(11), Supp: S344, 2010 (abstract).
99. Broen J, Gourh P, Vonk M, Beretta L, Rueda B, Geurts-von Bon L, Brouwer C, Mayes MD et al. Functional Variants in the Pre-B Cell Colony Enhancing Factor Gene Are Associated with Systemic Sclerosis Susceptibility and the Clinical Hallmark Pulmonary Arterial Hypertension. *Arthritis Rheum* 61(11), Supp: S346, 2010 (abstract).

100. Bodukam V, Hays RD, Maranian P, Furst DE, Seibold JR, Impens A, Mayes MD, Clements PJ, Khanna D. Association of Gastrointestinal Involvement and Depressive Symptoms in Patients with Systemic Sclerosis. *Arthritis Rheum* 61(11), Supp: S505, 2010 (abstract).
101. Sharif R, Mayes MD, Nicassio PM, Gonzalez EB, Draeger HT, McNearney TA, Nair DK, Reveille JD, Arnett FC, Assassi S. Determinants of Work Disability in Patients with Systemic Sclerosis: A Longitudinal Study of the GENISOS Cohort. *Arthritis Rheum* 61(11), Supp: S507, 2010 (abstract).
102. Sharif R, Fritzler MJ, Reveille JD, Assassi S, Mayes MD, Arnett FC. Genetic and Clinical Correlates of Anti-Fibrillarin (U2-RNP) Auto-Antibodies in African Americans with Systemic Sclerosis. *Arthritis Rheum* 61(11), Supp: S509, 2010 (abstract).
103. Assassi S, Charles J, Arnett FC, Sharif R, Lasky RE, Gonzalez EB, Draeger HT, McNearney TA, Agarwal SK, Gutala RV, Estrada-Y-Martin RM, Mayes MD, Eli Lilly & Co. Is Surfactant D or CC-Chemokine Ligand 18 Biomarkers for Interstitial Lung Disease in Systemic Sclerosis? *Arthritis Rheum* 61(11), Supp: S510, 2010 (abstract).
104. Leyva AL, Assassi S, Mayes MD, Nair DK, Fischbach M, Sharif R, Reveille JD, Gonzalez EB, McNearney TA. Longitudinal Fatigue Severity Scale Scores Correlate with Modifiable Psychosocial Variables in Early Systemic Sclerosis. *Arthritis Rheum*. 61(11), Supp: S511, 2010 (abstract).
105. McNearney TA, Sluka KA, Ahn CS, Reveille JD, Fischbach M, Mayes MD. Plasma Endogenous Met- and Leu-Enkephalin Levels are Decreased and Associated with Clinical and Laboratory Parameters in Early Systemic Sclerosis. *Arthritis Rheum* 61(11), Supp: S514, 2010 (abstract).
106. Assassi S, Sharif R, Lasky RE, McNearney TA, Nair DK, Estrada-Y-Martin RM, Draeger HT, Fritzler MJ, Reveille JD, Arnett FC, Mayes MD, Eli Lilly & Co. Predictors of Interstitial Lung Disease in Early Systemic Sclerosis: A Prospective Longitudinal Study. *Arthritis Rheum* 61(11), Supp: S514, 2010 (abstract).
107. Gorlova O, Martin JE, Rueda B, Koeleman P.C. B, Tereul M, Broen JC, Mayes MD, et al. Genome-Wide Association Study of Systemic Sclerosis Clinical Features Identifies New Disease Risk Variants. *Arthritis Rheum* 61(11), Supp: S930, 2010 (abstract).
108. Gordon J, Kamini D, Steen V, Horn EM, Hummers L, Bolster MB, Shapiro L, Frech T, Derk C, Dinesh K, Mayes MD, KGF, [title] 2011 ACR/ARHP Annual Scientific Meeting, Chicago, IL, November 4 -9, 2011.
109. Draeger H, Assassi S, Sharif R, Gonzalez EB, Harper BE, Lange RA, Mayes MD, Fascicular Block: A Predictor of Mortality In Early Systemic Sclerosis. *Arthritis Rheum* 63(10): Supp: S578, 2011 (abstract).
110. Harper, BE, Assassi S, Geslani G, Leung J, Bentz H, Gonzalez EB, Draeger HT, Nair D, Mayes MD. Marital Status in Systemic Sclerosis: Association with Pulmonary Function and Skin Involvement. *Arthritis Rheum* 63(10): Supp: S259, 2011 (abstract).

111. Khanna D, Seibold JR, Merkel PA, Mayes MD, Phillips K, Simms RW, Assassi S, Clements PJ, Furst DE. Construct Validity of the Saint George's Respiratory Questionnaire in an Observational Cohort of Patients with Early Diffuse Systemic Sclerosis. *Arthritis Rheum* 63(10): Supp: S262-3, 2011 (abstract).
112. Assassi S, Tan FK, Ying J, Gorlova OY, Harper BE, Draeger HT, Gonzalez EB, Estrada-Y-Martin RM, Charles J, Zhou X, Arnett FC, Reveille JD, Mayes MD. HLA *DQB1*03:02* Is a Marker for Severity of Interstitial Lung Disease in Systemic Sclerosis. *Arthritis Rheum* 63(10): Supp: S568, 2011 (abstract).
113. Bossini-Castillo L, Martin JE, Broen J, Simeon CP, Beretta L, Vonk MC, Carriera PE, Spanish Scleroderma Group, Riemekasten G, Hunzelmann N, Voskuyl AE, Schuerwegh A, Palm O, Hesselstrand R, Nordin A, Lunardi C, Shiels P, Van Laar JM, Herrick AL, Tan FK, Assassi S, Fonseca C, Mayes MD, Radstake T, Martin J. A Genome-Wide Association Study Follow-up Strategy Reveals the Association of *IL12RB2* Gene with Systemic Sclerosis in Caucasian Populations. *Arthritis Rheum* 63(10): Supp: S582-3, 2011 (Abstract).
114. Carmona FD, Gutala R, Simeón CP, Carreira PE, Ortego-Centeno N, Vicente-Rabaneda E, García-Hernández FJ, García de la Peña P, Fernández-Castro M, Martínez-Estupiñán L, Egurbide M-V, Spanish Scleroderma Group, Tsao BP, Gourh PR, Agarwal SK, Assassi S, Mayes MD, Arnett FC, Tan FK, Martín J. The IRF7 Region Is Associated with Anti-Centromere Autoantibody Production in Systemic Sclerosis Patients. *Arthritis Rheum* 63(10): Supp: S583, 2011 (Abstract).
115. Mayes MD, Gorlova OY, Bossini-Castillo L, Martin JE, Ying J, Gregersen PK, Lee AT, Assassi S, Agarwal SK, Tan FK, Reveille JD, Zhou X, Arnett FC, Wigley FM, Hummers LK, Perry M, Simeon CP, Carriera P, Ortego-Centeno N, Gonzalez-Gay M, The Spanish Scleroderma Group, Martin J. Immunochip Genotyping of 1,884 Systemic Sclerosis Cases and 4,774 Controls Reveals Novel Associations. *Arthritis Rheum* 63(10): Supp: S584, 2011 (Abstract).
116. Martin JE, Broen J, Gorlova OY, Vonk MC, Spanish Scleroderma Group, Voskuyl A, Schuerwegh A, Vanthuyne M, Smith V, Westhovens R, de Baere E, Kreuter A, Riemekasten G, Hesselstrand R, Nordin A, Palm O, Airo P, Hunzelmann N, Beretta L, Tan FK, Arnett FC, Mayes MD, Radstake T, Martin J, Koeleman BPC. Identification of Novel Genes Associated with Systemic Sclerosis Through Genome Wide Association Study Follow-up. *Arthritis Rheum* 63(10): Supp: S585, 2011 (Abstract).
117. Gordon JK, Doobay K, Horn E, Bolster MB, Shapiro LS, Khanna D, Frech TM, Fields K, Derk CT, Hummers LK, Mayes MD, Steen VD, PHAROS Investigators. Clinical and Hemodynamic Features of Scleroderma Patients with Pulmonary Venous Hypertension Versus Pulmonary Arterial Hypertension. *Arthritis Rheum* 63(10): Supp: S673-4, 2011 (Abstract).
118. Hinchcliff ME, Pennison M, Zimmerman J, Bellam N, Zeng Q, Huang CC, Pope RM, Sadim M, Wolf W, Edberg JC, Kimberly RP, Zhang K, Li J, Yi N, Canadian Scleroderma Research Group (CSRg), Scleroderma Registry Investigators, Mayes

2015

Ishmael
Lectureship



- MD, Varga J, Pasche B. *Transforming Growth Factor- β Receptor One Variant Is Associated with Constitutively Decreased Transforming Growth Factor- β Signaling and Risk for Systemic Sclerosis.* *Arthritis Rheum* 63(10): Supp: S821-2, 2011 (Abstract).
119. Martin JE, International Scleroderma Group, Radstake TRD, Tan FK, Arnett FC, Mayes MD, de Bakker P, Koeleman BPC, Martin J. Identification of Major Histocompatibility Complex Class II Alleles Associated with Systemic Sclerosis Through Imputation Strategy. *Arthritis Rheum* 63(10): Supp: S904, 2011 (Abstract).
120. Gourh PR, Tan FK, Rueda B., Arnett FC, Assassi S, Reveille JD, Radstake TRD, Mayes MD, Martin J, Agarwal SK. Gene-Gene Interactions in Interferon Pathway Gene-Mutations in European and American Scleroderma Cohorts. *Arthritis Rheum* 63(10): Supp: S909, 2011 (Abstract).
121. Stevens AM, Mayes MD, Reveille JD, Henstorf GR, Nelson JL. Human Leukocyte Antigen Alleles in Juvenile Onset Systemic Sclerosis. *Arthritis Rheum* 63(10): Supp: S909-10, 2011 (Abstract).
122. Sharif R, Mayes MD, Tan FK, Gorlova O, Hummers LK, Shah AA, Furst DE, Khanna D, Martin J, Bossini-Castillo L, Gonzalez EB, Draeger HT, Ying J, Agarwal SK, Arnett FC, Wigley FM, Assassi S. A Functional *IRF5* Variant Predicts Prognosis in Patients with Systemic Sclerosis. *Arthritis Rheum* 63(10): Supp: S945, 2011 (Abstract).
123. Seibold JR, Wigley FM, Schioppa E, Denton CD, Silver RM, Steen VD, Medsger TA Jr, Mayes MD, Chatterjee S, Chung L, Csuka ME, Khanna D, Frech TM, Molitor JA, Rothfield NF, Herrick AL, Simms RW, Pope JE, Rollins KD, Arneson C, Wade M, on behalf of DISTOL Investigators. Digital Ischemic Ulcers in Scleroderma Treated with Oral Treprostinil Diethanolamine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. *Arthritis Rheum* 63(10): Supp: S968-9, 2011 (Abstract).
124. Liu X, Mayes M, Tan F, Harper B, Gonzalez E, Draeger H, Sharif R, Reveille J, Arnette F, Assassi S: IL-8 and IL-10 Correlate with Severity of Interstitial Lung Disease in SSc. *Rheumatology* 51: Sii4, 2012.
125. Assassi S, Leyva A, Mayes M, Sharif R, Nair D, Fischbach M, Nguyen N, Reveille J, Gonzalez E, McNearney T: Modifiable Predictors of Fatigue in SSc: A Prospective Longitudinal Study of the GENISOS Cohort. *Rheumatology* 51: Sii22, 2012.
126. Assassi S, Mayes M, Liu X, Harper B, Gonzalez E, Draeger H, Zhou X, Khanna D, Furst D, Tan F: Global Gene Expression Profiling in Skin Identifies Transcripts Correlating with Severity of Interstitial Lung Disease in SSc. *Rheumatology* 51: Sii16-17, 2012.
128. Wang JC, Assassi S, Guo G, Tu WZ, Tan FK, Mayes MD, Reveille JD, Wu WY, Zou HJ, Zhao YQ, Chu HY, Liu J, Zhou XD: The Autoantibody Profile of Chinese Patients with SSc Differs Significantly from Other Ethnic Groups. *Rheumatology* 51: Sii23-4, 2012.
129. Mayes M, Gorlova O, Bossini-Castillo L, Martin E, Ying J, Gregersen P, Lee A, Assassi S, Agarwal S, Tan F, Reveille J, Zhou X, Wigley F, Hummers L, Arnett F,

2015

Ishmael
Lectureship



- Simeon C, Carreira P, Ortego N, Gonzalez-Gray M, Martin J: Novel Genetic Variants in Scleroderma Subphenotypes Identified by ImmunoChip in a Combined US and Spanish Cohort. *Rheumatology* 51: Sii34, 2012.
130. Harper B, Mayes M, Gonzalez E, Draeger H, Nair D, Agarwal S, Tan F, Assassi S: Is Fatigue Related to Cytokine Imbalance in Patients with SSc? *Rheumatology* 51: Sii89-90, 2012.
131. Sullivan K, Forshaug D, Furst D, Nash R, Mayes M, Crofford L, McSweeney P, Goldmuntz E, Keyes-Elstein L, Khanna D. Organ Function and Quality of Life Correlates at Randomization on the SCOT (Scleroderma: Cyclophosphamide or Transplantation) Trial. Presented at the 2nd Systemic Sclerosis World Congress, Madrid, Spain, Feb. 2-4, 2012. *Rheumatology Oxford*; 51(Supplement 2): ii1, 2012.
132. Sullivan K, Woolson R, Wallace P, Sempowski G, McSweeney P, Mayes M, Crofford L, Nash R, Furst D, Storek J. Lymphocyte Immunophenotypes at Entry on the SCOT Trial: Compared with Healthy Controls, Markedly Reduced T- and B-Cell Subsets Are Present in Subjects with SSc Treated or Not Treated with Prior DMARDs. Presented at the 2nd Systemic Sclerosis World Congress, Madrid, Spain, Feb. 2-4, 2012. *Rheumatology Oxford*; 51(Supplement 2): ii1, 2012.
137. Carmona F, Gutala R, Simeón CP, Carreira P, Ortego Centeno N, Vicente Rabaneda E, García Hernández FJ, García De La Peña P, Fernández Castro M, Martínez Estupiñán L, Egurbide MV, Tsao BP, Gourh P, Agarwal SK, Assassi S, Mayes MD, Arnett FC, Tan FK, Martín J. Association of the IRF7 Region with Anti-centromere Autoantibody Production in SSc. Presented at the 2nd Systemic Sclerosis World Congress, Madrid, Spain, Feb. 2-4, 2012. *Rheumatology Oxford*; 51(Supplement 2): ii24, 2012.
138. Mayes M, Gorlova O, Bossini-Castillo L, Martin E, Ying J, Gergersen P, Lee A, Assassi S, Agarwal S, Tan F, Reveille J, Zhou X, Wigley F, Hummers L, Arnett F, Simeon C, Carreira P, Ortego N, Gonzalez-Gay M, Martin J. Novel Genetic Variants in Scleroderma Subphenotypes Identified by ImmuneChip in a Combined US and Spanish Cohort. Presented at the 2nd Systemic Sclerosis World Congress, Madrid, Spain, Feb. 2-4, 2012. *Rheumatology Oxford*; 51(Supplement 2): ii34, 2012.
139. Khanna D, Berrocal V, Seibold JR, Merkel PA, Mayes MD, Phillips K, Simms RW, Assassi S, Clements PJ, Furst DE. Combined Response Index in Diffuse Systemic Sclerosis (CRISS) – Which External Anchors to Use When Developing the Index? Baseline Analysis. *Arthritis Rheum* 64(10): Supp: S41-2, 2012 (Abstract).
140. Liu X, Mayes MD, Reveille JD, Gonzalez EB, Harper BE, Draeger HT, Assassi S. C-Reactive Protein Predicts Long-Term Progression of Interstitial Lung Disease and Survival in Patients with Early Systemic Sclerosis. *Arthritis Rheum* 64(10): Supp: S372, 2012 (Abstract).
141. Gladue H, Furst D, Berrocal V, Seibold JR, Merkel PA, Mayes MD, Phillips K, Simms RW, Assassi S, Clements PJ, Maranian P, Khanna D. Comparison of Baseline

- Characteristics of the Combined Response Index for Systemic Sclerosis (CRISS) Cohort to Patients Enrolled in Clinical Trials of Diffuse Systemic Sclerosis. *Arthritis Rheum* 64(10): Supp: S628-9, 2012 (Abstract).
142. Liu X, Mayes MD, Tan FK, Wu M., Reveille JD, Harper BE, Draeger HT, Gonzalez EB, Assassi S. Interferon-Inducible Chemokines Correlate with Disease Severity in Systemic Sclerosis. *Arthritis Rheum* 64(10): Supp: S633, 2012 (Abstract).
143. Assassi S, Chang JT, Khanna D, Liu X, Furst D, Mayes MD. Does Skin Gene Expression Profile Predict Response to Imatinib? *Arthritis Rheum* 64(10): Supp: S633-4, 2012 (Abstract).
144. Assassi S, Chang JT, Tan FK, Wu M, Salazar Cintora GA, Zaheer I, Khanna D, Furst DE, Mayes MD. Correlates of Skin Gene Expression Profile in Systemic Sclerosis. *Arthritis Rheum* 64(10): Supp: S646-7, 2012 (Abstract).
145. Wu M, Blackburn MR, Assassi S, Liu X, Reveille JD, Tan FK, Agarwal SK, Mayes MD. Type I Interferon Associated Gene *IRF7* in the Pathogenesis of Fibrosis in Systemic Sclerosis (SSc). *Arthritis Rheum* 64(10): Supp: S968, 2012 (Abstract).
146. Bossini-Castillo L, Martin JE, Simeon CP, Beretta L, Gorlova OY, Vonk MC, Carreira P, the Spanish Scleroderma Group, Schuerwegh A, Voskuyl A, Hoffmann-Vold A-M, Hesselstrand R, Nordin A, Lunardi C, Van Laar J, Shiels P, Herrick A, Worthington J, Fonseca C, Denton CP, Assassi S, Koeleman BPC, Mayes MD, Radstake TRDJ, Martin J. Confirmation of *TNIP1A*s a Susceptibility Locus for Systemic Sclerosis in a Large Multicentre Study. *Arthritis Rheum* 64(10): Supp: S973, 2012 (Abstract).
147. Carmona FD, Cénit MC, Díaz-Gallo LM, Simeón CP, Carreira P, the Spanish Scleroderma Group, Hunzelmann N, Riemakasten G, Witte T, Kreuter A, Distler JHW, Shiels P, van Laar JM, Schuerwegh A, Vonk MC, Voskuyl A, Fonseca C, Denton C, Herrick A, Arnett FC, Tan FK, Assassi S, Radstake TRDJ, Mayes MD, Martin J. Differential Association of *IRAK1* and *MECP2* with Specific Systemic Sclerosis Phenotypes. *Arthritis Rheum* 64(10): Supp: S973-4, 2012 (Abstract).
148. Martin JE, Simeón CP, Ortego-Centeno N, Carreira P, Gonzalez-Gay MA, Hunzelmann N, Assassi S, Tan FK, Arnett FC, Zhou X, Radstake TRDJ, Mayes MD, de Bakker P, Martin J, Koeleman BPC. Identification of Major Histocompatibility Complex Class II Alleles Associated With Systemic Sclerosis Through Imputation Strategy. *Arthritis Rheum*. 65: S70, 2013 (Abstract).
149. Salazar G, Gebum K, Guo X, Wu M, Assassi S, Mayes MD, Reveille JD, Zhou X. DNA Methylation and Systemic Sclerosis. *Arthritis Rheum*. 65: S281, 2013 (Abstract).
150. Nandiwada S, Jaskowski T, Mayes MD, Satoh M, Tebo AE. Autoantibody Diversity in Scleroderma Patients with Antinucleolar Antibodies and Negative for Three Major Disease-specific Markers. *Arthritis Rheum*. 65: S287, 2013 (Abstract).
151. Wu M, Pedroza C, Salazar G, Zhou X, Reveille JD, Mayes MD, Assassi S. Plasma MCP-1 and IL-10 Levels Predict Long-Term Progression of Interstitial Lung Disease in Patients with Early Systemic Sclerosis. *Arthritis Rheum*. 65: S742, 2013 (Abstract).

152. Merz EL, Malcarne VL, Assassi S, Nair D, Graham T, Yellman B, Estrada-Y-Martin RM, Mayes MD. Biopsychosocial Typologies of Pain in a Cohort of Patients with Systemic Sclerosis. *Arthritis Rheum.* 65: S920-1, 2013 (Abstract).
153. Salazar G, Assassi S, Wigley FM, Furst DE, Hummers LK, Khanna D, Varga J, Schiopu E, Steen VD, Baron M, Hudson M, Pope JE, Hinchcliff ME, Fritzler MJ, Robinson DB, Simms RW, Silver RM, Frech TM, Fessler BJ, Molitor JA, Zamanian S, Jones N, Reveille JD, Arnett FC, Mayes MD. Antinuclear Antibody Negative Systemic Sclerosis Patients Have Less Vasculopathic Disease Manifestations. *Arthritis Rheum.* 65: S1104, 2013 (Abstract).
154. Mayes MD for the US Scleroderma GWAS Group, Bossini-Castillo L for the Spanish Scleroderma Group, Gorlova O, Martin JE, Zhou X, Chen W, Assassi S, Ying J, Reveille JD, Gregersen PK, Lee AT, Teruel M, Carmona FD, Koeleman BPC, Brown MA and the Immunochip Consortium, Denton CP, Barron M. for the Canadian Scleroderma Research Group, Broen J, Radstake TRDJ, Martin J. Immunochip Analysis Identifies New Susceptibility Loci for Systemic Sclerosis: Implications for Pathogenesis. *Arthritis Rheum.* 65: S1169, 2013 (Abstract).
155. Assassi S, Hudson M, Mayes MD, Walker J, Baron M, Stevens W, Patterson K, Graham T, Tatibouet S, Wick J, Stephenson M, Fritzler MJ. Anti-Fibrillarin Antibodies Are Associated with More Severe Gastrointestinal Involvement and Poorer Survival. *Arthritis Rheum.* 65: S1251-2, 2013 (Abstract).
156. Salazar GA, Assassi S, Wu M, Hagan J, Mayes MD. A3.34 The global microRNA profile of skin in systemic sclerosis. *Ann Rheum Dis.* 2014 Mar 1;73 Suppl 1:A55-6. PMID 24489251.
157. Assassi S, Swindell W, Wu M, Tan FK, Khanna D, Furst DE, Tashkin D, Jahan-Tigh R, Mayes MD, Gudjonsson J, Chang JT. Dissecting the Heterogeneity of Skin Gene Expression Patterns in Systemic Sclerosis. *Arthritis Rheum.* In press, 2013

B. Refereed Original Articles in Journals

1. Wysenbeek AJ, Mandel DR, **Mayes MD**, and Clough JD. Autoantibodies in systemic lupus erythematosus of late onset. *Cleve Clin Q* 52:119-122, 1985. PMID: 3875440
2. Bathon J, Jens P, Graves J, Hamrick R, and **Mayes MD**. The erythrocyte sedimentation rate in end-stage renal failure. *Am J Kidney Dis* 10:34-40, 1987. PMID: 3605082
3. **Mayes MD**, Walker ER, Frederickson RG, Prince RK, and DiBartolomeo AG. The characterization of normal and scleroderma skin fibroblasts in a collagen gel matrix. *J Rheumatol* 15:268-275, 1988. PMID: 3283357
4. Freedman RR, Sabharwal SC, Ianni P, Desai N, Wenig P, and **Mayes MD**. Non-neural beta-adrenergic vasodilating mechanisms in temperature biofeedback. *Psychosom Med* 50: 394-401, 1988. PMID: 2842815

5. Freedman RR, Morris M, Norton DA, Masselink D, Sabharwal SC, and **Mayes MD**. Physiological mechanism of digital vasoconstriction training. *Biofeedback SelfRegul.* 13:299-305, 1988. PMID: 3248221
6. Walker ER, Frederickson RG, and **Mayes MD**. The mineralization of elastic fibers and alterations of extracellular matrix in pseudoxanthoma elasticum. Ultrastructure, immunocytochemistry, and X-ray analysis. *Arch Dermatol* 125: 70-76, 1989. PMID: 2910208
7. Freedman RR, Sabharwal SC, Desai N, Wenig P, and **Mayes MD**. Increased alpha-adrenergic responsiveness in idiopathic Raynaud's disease. *Arthritis Rheum* 32:61-65, 1989. PMID: 2536282
8. Freedman RR, **Mayes MD**, and Sabharwal SC. Induction of vasospastic attacks despite digital nerve block in Raynaud's disease and phenomenon. *Circulation* 80:859-862, 1989. PMID: 2791249
9. Freedman RR, **Mayes MD**, and Sabharwal SC. Digital nerve blockade in Raynaud's disease. *Circulation.* 80:123-124, 1989. PMID: 2598451
10. Karvonen RL, Negendank WG, Fraser SM, **Mayes MD**, An T, and Fernandez-Madrid F. Articular cartilage defects of the knees: Correlation between magnetic resonance imaging and gross pathology. *Ann Rheum Dis* 49:672-675, 1990. PMID: 2241283
11. Freedman RR, Keegan D, Migaly P, Galloway MP, and **Mayes MD**. Plasma catecholamines during behavioral treatments for Raynaud's Disease. *Psychosom Med* 53:433-439, 1991. PMID: 1924655
12. Freedman RR, Moten M, Migaly P, and **Mayes MD**. Cold-induced potentiation of α_2 -adrenergic vasoconstriction in primary Raynaud's disease. *Arthritis Rheum* 36:685-690, 1993. PMID: 8387786
13. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, Silman A, Allegar N, Varga J, Massa M, Wigley FW, Ingenito F, Weisman M, Needleman B, Martin RW, McCloskey D, Moreland LW, **Mayes MD**, Lally EV, Unanue M, Collier DH, Weiner S, Weinstein A, Medsger TA Jr., Andrews B, Dixon M, White B and Furst DE. Skin thickness score in systemic sclerosis (SSc): An assessment of inter-observer variability in three independent studies. *J Rheum* 20:1892-1896, 1993.
14. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr, Steen VD, Varga J, Jimenez S, **Mayes MD**, Clements PJ, Weiner SR, Porter J, Ellman M, Wise C, Kaufman LD, Williams J, and Dole W. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. *Ann Intern Med* 120:199-206, 1994. PMID: 7506013
15. Clegg DO, Reading JC, **Mayes MD**, Seibold JR, Harris C, Wigley FM, Ward JR, Pisko EJ, Weisman MH, Lee P, Moreland LW, Neuner R, Gall EP, Clements P, Spindler J, and Lally EV. Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma. *J Rheum* 21:105-110, 1994. PMID: 8151563
16. Freedman RR, Woodward S, and **Mayes MD**. Nonneural mediation of

- digital vasodilation during menopausal hot flashes. *Gynecol Obstet Invest* 38:206-209, 1994. PMID: 8001877
17. Schottenfeld D, Burns CJ, Gillespie BW, Laing TJ, **Mayes MD**, Heeringa SG, and Alcsér KH. The design of a population based case-control study of systemic sclerosis (scleroderma): commentary on the University of Michigan study. *J Clin Epidemiol* 48:583-586, 1995. PMID: 7722615
 18. Kirk TZ, Mark ME, Chua CC, Chua BH, and **Mayes MD**. Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and TIMP-1 (Tissue Inhibitor of Metalloproteinase) with two forms of TIMP-1. *J Biol Chem* 270:3423-3428, 1995. PMID: 7852429
 19. Clements PJ, Collier DH, Dixon M, Furst DE, Ingenito F, Lachenbruch PA, Lally EV, Martin RW, Massa M, **Mayes MD**, McCloskey DA, Medsger, Jr TA, Moreland LW, Seibold JR, Steen V, Varga J, Weiner S, Weinstein A, Weisman M, White B, and Wigley FM. Inter and intra-observer variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis (SSc). *J Rheumatol* 22:1281-1285, 1995. PMID: 7562759
 20. Moreland LW, Pratt PW, **Mayes MD**, Postlethwaite A, Weisman MH, Schnitzer T, Lightfoot R, Calabrese L, Zelinger DJ, Woody JN, and Koopman WJ. Double-blind, placebo-controlled multi-center trial using chimeric monoclonal anti-CD4 antibody cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. *Arthritis Rheum* 38:1581-1588, 1995. PMID: 7488278
 21. Freedman RR, Baer RP, **Mayes MD**. Blockade of vasospastic attacks by alpha-2, but not alpha-1 adrenergic antagonists in idiopathic Raynaud's disease. *Circulation* 92:1448-1451, 1995. PMID: 7664425
 22. Freedman RR, **Mayes MD**. Familial aggregation of primary Raynaud's disease. *Arthritis Rheum* 39:1189-1191, 1996. PMID: 8670329
 23. Burns CJ, Laing TJ, Gillespie BW, Heeringa SG, Alcsér KH, **Mayes MD**, Wasko MCM, Cooper BC, Garabrant DH, Schottenfeld D. The epidemiology of scleroderma among women: Assessment of risk from exposure to silicone and silica. *J Rheum* 23:1904-1911, 1996. PMID: 8923364
 24. Keenan PA, Jacobson MW, Soleymani RM, **Mayes MD**, Stress ME, Yaladoo DT. The effect on memory of chronic prednisone treatment in patients with systemic disease. *Neurology* 47:1396-1402, 1996. PMID: 8960717
 25. Laing TJ, Gillespie BW, Toth MB, **Mayes MD**, Gallavan Jr. RH, Burns CJ, Johanns JR, Cooper BC, Keroack BJ, Wasko MCM, Lacey Jr. JV, Schottenfeld D. Racial differences in scleroderma among Michigan women. *Arthritis Rheum* 40:734-742, 1997. PMID: 9125258
 26. **Mayes MD**, Buyon JP, Pachman LM, Fleckman P, Giannini EH.

- Connective Tissue Disease Registries. *Arthritis Rheum* 40:1556-1559, 1997.PMID: 9324008
27. Seibold J, Clements P, Furst D, **Mayes M**, McCloskey D, Moreland L, White B, Wigley F, Rocco S, Erikson M, Hannigan J, Martin E, Amento E. Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosis. *J Rheum* 25:302-307, 1998.PMID: 9489823
 28. Doss B, Jacques SM, Atty S, **Mayes MD**, Qureshi F. Maternalscleroderma: placental findings and perinatal outcome. *HumPathol* 29:1524-1530, 1998. PMID: 9865842
 29. Wigley FM, Korn JH, Csuka ME, Medsger Jr. TA, Rothfield NF, Ellman M, Martin R, Collier DH, Weinstein A, Furst DE, Jimenez SA, **Mayes MD**, Merkel PA, Gruber B, Kaufman L, Varga J, Bell P, Kern J, Marrott P, White B, Simms RW, Phillips AC, Seibold JR. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double blind study. *Arthritis Rheum* 41:670-677, 1998. PMID: 9550476
 30. Kirk TZ, **Mayes MD**. IL-1 rescues scleroderma myofibroblast from serum-starvation-induced cell death. *BiochemBiophys Res Commun (BBRC)* 255:129-132, 1999. PMID: 10082667
 31. Clements PJ, Furst D, Wong W-K, **Mayes M**, White B, Wigley F, Weisman M, Barr W, Moreland L, Medsger Jr. T, Steen V, Martin R, Collier D, Weinstein A, Lally E, Varga J, Weiner S, Andrews B, Abeles M, Seibold J. High-dose vs low-dose D-penicillamine in early diffuse systemic sclerosis. Analysis of a two-year, double-blind, randomized, controlled clinical trial. *Arthritis Rheum* 42:1194-1203, 1999. PMID: 10366112
 32. Lacey Jr JV, Garabrant DH, Laing TJ, Gillespie BW, **Mayes MD**, Cooper BC, Schottenfeld D. Petroleum distillate solvents as risk factors for undifferentiated connective tissue disease (UCTD). *Am J Epidemiol* 149:761-770, 1999.PMID: 10206626
 33. Clements PJ, Wong W-K, Hurwitz EL, Furst DE, Mayes M, White B, Wigley F, Weisman M, Barr W, Moreland L, Medsger Jr. T, Steen V, Martin R, Collier D, Weinstein A, Lally E, Varga J, Weiner S, Andrews B, Abeles M, Seibold J. Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis. *Arthritis Rheum* 42:2372-2380, 1999. PMID: 10555033
 34. Freedman RR, Girgis RE, **Mayes MD**. Endothelial and adrenergic dysfunction in Raynaud's phenomenon and scleroderma. *J Rheumatol* 26:2386-2388, 1999.PMID: 10555897
 35. Freedman RR, Girgis RE, **Mayes MD**. Acute effect of nitric oxide on Raynaud's phenomenon in scleroderma. *Lancet* 354:739, 1999, Research Letter.PMID: 10475187
 36. Seibold JR, Korn JH, Simms R, Clements PJ, Moreland LW, Mayes MD, Furst DE, Rothfield N, Steen V, Weisman M, Collier D, Wigley FM, Merkel PA, Csuka ME, Hsu V,

- Rocco S, Erikson M, Hannigan J, Harkonen WS, Sanders ME. Recombinant Human Relaxin in the treatment of scleroderma: A randomized double-blind, placebo-controlled trial. *Ann Intern Med* 132:871-879, 2000. PMID: 10836913
37. Clements PJ, Hurwitz EL, Wong W-K, Seibold J, Mayes M, White B, Wigley F, Weisman M, Barr W, Moreland L, Medsger Jr. T, Steen V, Martin R, Collier D, Weinstein A, Lally E, Varga J, Weiner S, Andrews B, Abeles M, and Furst DE. Skin thickness score as a predictor and correlate of outcome in sclerosis: high-dose vs low-dose Penicillamine trial. *Arthritis Rheum* 43:2445-2454, 2000. PMID: 11083267
38. Freedman RR, Girgis RE, **Mayes MD**. Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma. *J Rheumatol* 28:119-121, 2001. PMID: 11196511
39. Furst DE, Clements PJ, Wong WK, **Mayes MD**, Wigley F, White B, Weisman M, Barr W, Moreland L, Martin R, Medsger Jr. TA, Steen V, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Peter JB, Seibold JR. Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial. *Rheumatology (Oxford)* 40:615-622, 2001. PMID: 11426017
40. Arnett FC, Cho M, Chatterjee S, Aguilar MB, Reveille JD, **Mayes MD**. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three US cohorts. *Arthritis Rheum* 44:1359-1362, 2001. PMID: 11407695
41. Fursan PB, **Mayes MD**, Freedman RR. Effect of temperature and modulators of protein tyrosine kinase activity on the reactivity of isolated venules in secondary Raynaud's phenomenon. *J Rheumatol*, 28:2263-2268, 2001. PMID: 11669167
42. Clements PJ, Wong WK, Hurwitz EL, Furst DE, **Mayes M**, White B, Wigley F, Weisman M, Barr W, Moreland L, Medsger TA Jr, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Seibold JR. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. *Arthritis Rheum* 44:653-661, 2001. PMID: 11263780
43. Laing TJ, Schottenfeld D, Lacey JR Jr, Gillespie BW, Garabrant DH, Cooper BC, Heeringa SG, Alcsér KH, **Mayes MD**. Potential risk factors for undifferentiated connective tissue disease among women: implanted medical devices. *Am J Epidemiology* 154:610-617, 2001. PMID: 11581094
44. Girgis RE, Gugnani MK, Abrams J, **Mayes MD**. Partitioning of alveolar and conducting airway nitric oxide in scleroderma lung disease. *Am J Respir Crit Care Med* 165:1587-1591, 2002. PMID: 12070057
45. Doss BJ, Qureshi F, **Mayes MD**, Jacques SM. Vascular and connective tissue histopathologic alterations of the female lower genital tract in scleroderma. *J Rheumatol* 29:1384-1387, 2002. PMID: 12136892

46. McSweeney PA, Nash RA, Sullivan KM, Storek J, Crofford LJ, Dansey R, **Mayes MD**, McDonagh KT, Nelson JL, Gooley TA, Holmberg LA, Chen CS, Wener MH, Ryan K, Sunderhaus J, Russell K, Rambharose J, Storb R, Furst DE. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. *Blood* 100:1602-1610, 2002. PMID: 12176878
47. Merkel PA, Herlyn K, Martin RW, Anderson JJ, **Mayes MD**, Bell P, Korn JH, Simms RW, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman MH, Collier DH, Weinstein A, Furst DE, Jimenez SA, White B, Seibold JR, Wigley FM: Scleroderma Clinical Trials Consortium. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. *Arthritis Rheum* 46:2410-2420, 2002. PMID: 12355489
48. DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL, **Mayes M**, White B, Wigley F, Barr W, Moreland L, Medsger TA Jr, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Clements PJ. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-Penicillamine in early diffuse systemic sclerosis trial. *Arthritis Rheum* 46:2983-2989, 2002. PMID: 12428241
49. Garabrant DH, Lacey JV Jr, Laing TJ, Gillespie BW, **Mayes MD**, Cooper BC, Schottenfeld D. Scleroderma and solvent exposure among women. *Am J Epidemiol* 157:493-500, 2003. PMID: 12631538
50. **Mayes MD**, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, Schottenfeld D. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large U.S. population. *Arthritis Rheum* 48:2246-2255, 2003. PMID: 12905479
51. Nash RA, Dansey R, Storek J, Sullivan KM, Georges GE, Bowen JD, Holmberg LA, Kraft GH, **Mayes MD**, McDonagh KT, Chen CS, Dipersio J, LeMaistre CF, Pavletic S, Sunderhaus J, Furst DE, McSweeney PA. Epstein-Barr virus-associated post-transplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. *Biol Blood Marrow Transplant.* 9:583-591, 2003. PMID: 14506660
52. **Mayes MD**, O'Donnell D, Rothfield NF, Csuka ME. Minocycline is not effective in systemic sclerosis (SSc): Results of an open-label multicenter trial. *Arthritis Rheum* 50:553-557; 2004. PMID: 14872498
53. Clements PJ, Seibold JR, Furst DE, **Mayes, M**, White B, Wigley F, Weisman MD, Barr W, Moreland L, Medsger TA Jr, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga, J, Weiner SR, Andrews B, Abeles M, Wong WK. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: Lessons Learned. *Semin Arthritis Rheum* 33:249-263, 2004. PMID: 14978663
54. Chatterjee S, Mark ME, Wooley PH, Lawrence WD, **Mayes MD**. Increased dermal elastic fibers in the tight skin mouse. *Clin Exp Rheumatol.* 22:617-620, 2004. PMID: 15485016

55. Khorshid O, Hosing C, Bibawi S, Ueno N, Reveille J, **Mayes MD**, Champlin RE. Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus. *J Rheumatol (Case Report)* 31:2513-6, 2004. PMID: 15570660
56. Korn JH, **Mayes M**, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, Hsu V, Guillevin S, Chatterjee S, Peters H, Coppock J, Herrick A, Merkel P, Simms R, Denton CP, Furst D, Nguyen N, Gaitonde M, Bodin F, Black C, for the RAPIDS-1 Study Group. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. *Arthritis Rheum* 50:3985-93, 2004. PMID: 15593188
57. Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, Sterz M, Chung J, Fitzgerald JD, Seibold JR, Varga J, Theodore A, Wigley FM, Silver RM, Steen VD, **Mayes MD**, Connolly MK, Fessler BJ, Rothfield NF, Mubarak K, Molitor J, Tashkin DP; Scleroderma Lung Study Group. Correlation of the degree of dyspnea score with health-related quality of life, functional abilities and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. *Arthritis Rheum* 52:592-600, 2005. PMID: 15692967
58. Furspan PB, Chatterjee S, **Mayes MD**, Freedman RR. Cooling-induced contraction and protein tyrosine kinase activity of isolated arterioles in secondary Raynaud's phenomenon. *Rheumatology (Oxford)* 44:488-94, 2005. PMID: 15695304
59. Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, Korn JH, Merkel PA, Rothfield N, Wigley FM, Moreland LW, Silver R, Steen VD, Weisman M, **Mayes MD**, Collier D, Medsger Jr TA, Seibold JR; Relaxin Study Group; Scleroderma Clinical Trials Consortium. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index (HAQ-DI) in a Systemic Sclerosis Clinical Trial. *J Rheumatol* 32:832-40, 2005. PMID: 15868618
60. Wigley FM, Lima JA, **Mayes M**, McLain D, Chapin JL, Ward-Able C. The Prevalence of Undiagnosed Pulmonary Arterial Hypertension in Subjects with Connective Tissue Disease at the Secondary Healthcare Level of Community-Based Rheumatologists (UNCOVER Study). *Arthritis Rheum* 52:2125-32, 2005. PMID: 15986394
61. Tan FK, Hildebrand BA, Lester MS, Stivers DN, Pounds S, Zhou X, Wallis DD, Milewicz DM, Reveille JD, **Mayes MD**, Jin L, Arnett FC Jr. Classification analysis of the transcriptome of nonlesional cultured dermal fibroblasts from systemic sclerosis patients with early disease. *Arthritis Rheum* 52:865-76, 2005. PMID: 15751056
62. Chatterjee S, Dombi GW, Severson RK, **Mayes MD**. Risk of Malignancy in Scleroderma: a population-based cohort study. *Arthritis Rheum* 52: 2415-24, 2005. PMID 16052585

63. Assassi S, **Mayes MD**, McNearney T, Fischbach M, Reveille JD, Arnett FC, Tan FK. Polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in systemic sclerosis. *Am J Med* 18:907-11, 2005. PMID 16084185
64. Tan FK, Zhou X, Marcum C, Gourh P, Guo X, **Mayes MD**, Jin L, Arnett FC, Jr. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. *Rheumatology (Oxford)* 45:694-702, 2006. PMID 16418202
65. Gardner H, Trojanowska M, Smith E, Pannu J, Shearstone J, Bandaru R, Tan FK, Crowl T, Lynes M, Jablonska S, Blaszczyk M, **Mayes MD**. Gene Profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. *Arthritis Rheum* 54:1961-73, 2006. PMID 16736506
66. Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, **Mayes MD**, White B, Wigley FF, Weisman M, Barr W, Moreland L, Medsger Jr TA, Steen VD, Martin RW, Collier D, Weinstein A, Lally EE, Varga J, Weiner SR, Andrews B, Abeles M, Clements PJ. Minimally important differences in diffuse systemic sclerosis: results from the D-Penicillamine study. *Ann Rheum Dis* 65(10):1325-9, 2006. PMID 16540546
67. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, **Mayes M**, Parsley E, Mubarak K, Connolly MK, Golden J, Oلمان M, Fessler B, Rothfield N, Metersky M; Scleroderma Lung Study Research Group. Cyclophosphamide versus Placebo in Scleroderma Lung Disease. *N Engl J Med* 2006 Jun 22;354(25):2655-66. PMID 16790698
68. Wu SP, Leng L, Feng Z, Liu N, Zhao H, McDonald C, Lee A, Arnett FC, Gregersen PK, **Mayes MD**, Bucala R. Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. *Arthritis Rheum* Nov;54(11):3661-9, 2006. PMID 17075815
69. McNearney TA, Reveille JD, Fischbach M, Friedman AW, Lisse JR, Goel N, Tan FK, Zhou X, Ahn C, Feghali-Bostwick CA, Fritzler M, Arnett FC, **Mayes MD**. Pulmonary involvement in systemic sclerosis: Associations with genetic, serologic, sociodemographic, and behavioral factors. *Arthritis Rheum* 52 (2):318-26, 2007. PMID 17330281
70. Gourh P, Tan FK, Assassi S, Ahn CW, McNearney TA, Fischbach M, Arnett FC, **Mayes MD**. Association of the PTPN22 R620W Polymorphism with anti-topoisomerase-I and anticentromere antibody-positive systemic sclerosis. *Arthritis Rheum* Dec;54(12):3945-53, 2006. PMID 17133608
71. Alkassab F, Gourh P, Tan FK, McNearney T, Fischbach M, Ahn C, Arnett FC, **Mayes MD**. An allograft inflammatory factor 1 (AIF1) single nucleotide polymorphism (SNP) is associated with anticentromere antibody positive systemic sclerosis. *Rheum Oxford*, 46(8):1248-51, 2007. PMID 17522098

72. Denton CP, Merkel P, Furst D, Khanna D, Emery P, Hsu V, Silliman N, Streisand J, Powell J, Akesson A, Coppock J, Hoogen, F, Herrick A, **Mayes M**, Veale D, Haas J, Ledgetter S, Korn J, Black CM, Seibold JR. Cat-192 Study Group; Scleroderma Clinical Trials Consortium. Recombinant human anti-TGFβ1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled Phase I/II Trial of CAT-192. *Arthritis Rheum* Jan;56(1):323-33, 2007. PMID 17195236
73. Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, **Mayes M**, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Clements PJ; Scleroderma Lung Study Group. Impact of Oral Cyclophosphamide on Health-Related Quality of Life in Patients with active Scleroderma Lung Disease: Results from the Scleroderma Lung Study. *Arthritis Rheum* 56(5):1676-84, 2007. PMID 17469162
74. Nash RA, McSweeney PA, Crofford LJ, Abidi M, Chen C-S, Godwin D, Gooley TA, Holmberg L, Henstorf G, LeMaistre F, **Mayes MD**, McDonagh KT, McLaughlin B, Moliter JA, Nelson JL, Shulman H, Storb R, Viganego F, Wener MH, Seibold JR, Sullivan KM, Furst DE. High-Dose Immunosuppressive Therapy (HDIT) and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the U.S. multicenter pilot study. *Blood* 110(8):1388-96, 2007. PMID 12176878
75. Gazi H, Pope JE, Clements P, Medsger TA, Martin RW, Merkel P, Kahaleh B, Wollheim F, Baron M, Csuka ME, Emery P, Belch JF, Hayat S, Lally EV, Korn JH, Czirjak L, Herrick A, Voskuyl AE, Bruehlmann P, Inanc M, Furst DE, Black C, Ellman M, Moreland LW, Rothfield NF, Hsu V, **Mayes M**, McKown KM, Krieg T, Seibold JR. Outcome measurements in scleroderma: results from a Delphi exercise. *J Rheum* 34(3):501-9, 2007. PMID 17299843
76. Suarez-Almazor ME, Kallen MA, Roundtree AK, **Mayes M**. Disease and symptom burden in systemic sclerosis: a patient perspective. *J Rheumatol* Aug; 34:1718-26, 2007. PMID 17611983
77. Alkassab F, **Mayes MD**. Images in Rheumatology: Overlap of Systemic Sclerosis and Rheumatoid Arthritis. *J Rheum* 2007(8); 34:1593-4. PMID 17522098
78. Assassi S, Arnett FC, Reveille JD, Gourh P, Mayes MD. Clinical, immunological, and genetic features of familial systemic sclerosis. *Arthritis Rheum* 2007 Jun;56(6):2031-7. PMID 17530643
79. Clements PJ, Roth MD, Elashoff R, Tashkin DP, Goldin J, Silver RM, Sterz M, Seibold JR, Schraufnagle D, Simms RW, Bolster M, Wise RA, Steen V, **Mayes MD**, Connolly K, Metersky M, Furst DE. Scleroderma Lung Study (SLS): Differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. *Ann Rheum Dis* 2007, Dec;66(12)1641-7. PMID 17485423
80. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, Goldin J, Arriola E, Strange C, Bolster MB, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D,

- Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, **Mayes M**, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rithfield N, Metersky M. Effect of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. *Am J Resp Crit Care Med* 176:1026-34, 2007. PMID 17717203
81. Wang F, Garza LA, Cho S, Kafi R, Hammerberg C, Quan T, Hamilton T, **Mayes M**, Ratanatharathorn V, Voorhees JJ, Fisher GJ, Kang S. Effect of increased pigmentation on the antifibrotic response of human skin to UV-A1 phototherapy. *Arch Dermatol* 2008 Jul;144(7):851-8. PMID 18645136
82. Khanna D, Lovell DJ, Giannini E, Clements PJ, Merkel PA, Seibold JR, Matucci-Cerinic M, Denton CP, **Mayes MD**, Steen VD, Varga J, Furst DE, for the other coauthors of the Scleroderma Clinical Trial Consortium. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. *Ann Rheum Dis* 2008 May;67(5) 703-9. PMID 17893248
83. Khanna D, Hays RD, Park GS, Braun-Moscovici Y, **Mayes MD**, McNearney TA, Hsu V, Clements PJ, Furst DE. Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument. *Arthritis Rheum* Oct 15;57(7):1280-1286, 2007. PMID 17907224
84. Postlethwaite AE, Wong WK, Clements P, Chatterjee S, Fessler BJ, Kang AH, Korn J, **Mayes M**, Merkel PA, Molitor JA, Moreland L, Rothfield N, Simms RW, Smith EA, Spiera R, Steen V, Warrington K, White B, Wigley F, Furst DE. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. Oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. *Arthritis Rheum.* 2008 Jun;58(6):1810-22. PMID 18512816
85. Merkel PA, Silliman NP, Denton CP, Furst DE, Khanna D, Emery P, Hsu VM, Streisand JB, Polisson RP, Akesson A, Coppock J, van den Hoogen F, Herrick A, **Mayes MD**, Veale D, Seibold JR, Black CM, Korn JH; CAT-192 Research Group; Scleroderma Clinical Trials Consortium. Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. *Arthritis Rheum.* 2008 May 15;59(5):699-705. PMID 18438905
86. Distler O, Behrens F, Pittrow D, Huscher D, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Furst DE; EPOSS-Omeract Group. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. *Arthritis Rheum.* 2008 Jun 15;59(6):867-75. PMID 18512721
87. Goldin JG, Lynch DA, Stollo DC, Suh RD, Schraufnagel DE, Clements PJ, Elashoff RM, Furst DE, Vasunilashorn S, McNitt-Gray MF, Brown MS, Roth MD, Tashkin DP; Scleroderma Lung Study Research Group. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. *Chest* 2008 Aug;134(2):358-67. PMID 18641099

88. Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S, Hsu V, Rothfield N, Steen V, Martin RW, Smith E, **Mayes M**, Simms R, Pope J, Kahaleh B, Csuka ME, Gruber B, Collier D, Sweiss N, Gilbert A, Dechow FJ, Gregory J, Wigley FM. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: A randomized, controlled trial. *Arthritis Rheum* 2009 Feb 26;60(3):870-77. PMID 19248104
89. **Mayes, MD**, Whittum-Hudson JA, Oszust C, Gérard HC, Hudson AP. Lack of evidence for bacterial infections in skin in patients with systemic sclerosis. *Am J Med Sci.* 2009 Apr;337(4):233-5. PMID 19402205
90. Khanna D, Clements PJ, Furst DE, Korn JH, Ellman M, Rothfield N, Wigley FM, Moreland LW, Silver R, Kim YH, Steen VD, Firestein GS, Kavanaugh AF, Weisman M, **Mayes MD**, Collier D, Csuka ME, Simms R, Merkel PA, Medsger TA Jr, Sanders ME, Maranian P, Seibold JR; Relaxin Investigators and the Scleroderma Clinical Trials Consortium. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: A randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2009 Apr;60(4):1102-11. PMID 19333948
91. McNearney TA, Hunnicutt SE, Fischbach M, Friedman AW, Aguilar M, Ahn CW, Reveille JD, Lisse JR, Baethge BA, Goel N, **Mayes MD**; GENISOS Study Group. Perceived functioning has ethnic-specific associations in systemic sclerosis: another dimension of personalized medicine. *J Rheumatol* 2009 Dec;36(12):2724-32. PMID 19918038 pmcid
92. Assassi S, Fritzler MJ, Arnett FC, Norman GL, Shah KR, Gourh P, Manek N, Perry M, Ganesh D, Rahbar MH, **Mayes MD**. Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. *J Rheumatol* 2009 Oct;36(10):2250-6. PMID 19723904 pmcid
93. Gourh P, Agarwal SK, Divecha D, Assassi S, Paz G, Arora-Singh RK, Reveille JD, Shete S, **Mayes MD**, Arnett FC, Tan FK. Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: Evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. *Arthritis Rheum* 2009 Dec;60(12):3794-806. PMID 19950257 pmcid
94. Assassi S, Del Junco D, Sutter K, McNearney TA, Reveille JD, Karnavas A, Gourh P, Estrada-Y-Martin RM, Fischbach M, Arnett FC, **Mayes, MD**. Clinical and genetic factors predictive of mortality in early systemic sclerosis. *Arthritis Rheum* 2009 Oct 15;61(10):1403-11. PMID 19790132 pmcid
95. Agarwal SK, Gourh P, Shete S, Paz G, Divecha D, Reveille JD, Assassi S, Tan FK, **Mayes MD**, Arnett FC. Association of interleukin23 receptor polymorphisms with anti-topoisomerase-I positivity and pulmonary hypertension in systemic sclerosis. *J Rheumatol* 2009 Dec;36(12):2715-23. PMID 19918037.pmcid
96. Arnett FC, Gourh P, Shete S, Ahn CW, Honey R, Agarwal SK, Tan FK, McNearney T, Fischbach M, Fritzler MJ, **Mayes MD**, Reveille JD. Major histocompatibility complex (MHC) class II alleles, haplotypes, and epitopes which confer

- susceptibility or protection in systemic sclerosis: Analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. *Ann Rheum Dis* 2010 May;69(5):822-7. PMID 19596691 pmcid
97. Karp DR, Marthandan N, Marsh SG, Ahn C, Arnett FC, DeLuca DS, Diehl AD, Dunivin R, Eilbeck K, Feolo M, Guidry PA, Helmberg W, Lewis S, **Mayes MD**, Mungall C, Natale DA, Peters B, Petersdorf E, Reveille JD, Smith B, Thomson G, Waller MJ, Scheuermann RH. Novel sequence feature variant type analysis of the HLA genetic association in systemic sclerosis. *Hum Mol Genet* 2010 Feb 15;19(4):707-19. PMID 19933168
98. Gourh P, Arnett FC, Tan FK, Assassi S, Divecha D, Paz G, McNearney T, Draeger H, Reveille JD, **Mayes MD**, Agarwal SK. Association of *TNFSF4* (OX40L) polymorphisms with susceptibility to systemic sclerosis. *Ann Rheum Dis* 2010 Mar;69(3):550-5. PMID 19778912
99. Assassi S, **Mayes M**, Arnett FC, Gourh P, Agarwal SK, McNearney TA, Chaussabel D, Oommen N, Fischbach M, Shah KR, Charles J, Pascual V, Reveille JD, Tan FK. Systemic sclerosis and lupus: points in an interferon-mediated continuum. *Arthritis Rheum* 2010 Feb;62(2):589-98. PMID 20112391
100. Zhou X, Lee JE, Arnett FC, Xiong M, Park MY, Yoo YK, Shin ES, Reveille JD, **Mayes MD**, Kim JH, Song R, Choi JY, Park JA, Lee YJ, Lee EY, Song YW, Lee EB. HLA-DPB1 and DPB2 are genetic loci for systemic sclerosis: A genome-wide association study in Koreans with replication in North Americans. *Arthritis Rheum* 2009 Dec;60(12):3807-14. PMID 19950302
101. Broen J, Gourh P, Rueda B, Coenen M, **Mayes M**, Martin J, Arnett F, Radstake TR, European Consortium on Systemic Sclerosis Genetics. The FAS -670A>G polymorphism influences the susceptibility to systemic sclerosis phenotypes. *Arthritis Rheum* 2009 Dec;60(12):3815-3820. PMID 19950259
102. Khanna D, Distler O, Avouac J, Behrens F, Clements PJ, Denton C, Foeldvari I, Giannini E, Huscher D, Kowal-Bielecka O, Lovell D, Matucci-Cerinic M, **Mayes M**, Merkel PA, Nash P, Opitz CF, Pittrow D, Rubin L, Siebold JR, Steen V, Strand CV, Tugwell PS, Varga J, Zink A, Furst DE; CRISS; EPOSS. Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). *J Rheumatol* 2009 Oct;36(10):2356-61. PMID 19820225
103. Cockrill T, del Junco DJ, Arnett FC, Assassi S, Tan FK, McNearney T, Fischbach M, Perry M, **Mayes MD**. Separate influences of birth order and gravidity/parity on the development of systemic sclerosis. *Arthritis Care Res (Hoboken)*. 2010 Mar;62(3):418-24. PMID 20391489
104. Gourh P, Arnett FC, Assassi S, Tan FK, Huang M, Diekman L, **Mayes MD**, Reveille JD, Agarwal SK. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. *Arthritis Res Ther*. 2009 Oct 2;11(5):R147. PMID 19799786

105. McNearney TA, Sallam HS, Hunnicutt SE, Doshi D, Wollaston DE, **Mayes MD**, Chen JD. Gastric slow waves, gastrointestinal symptoms and peptides in systemic sclerosis patients. *Neurogastroenterol Motil.* 2009 Dec;21(12):1269-e120. PMID 19566588
106. Rueda B, Gourh P, Broen J, Agarwal SK, Simeon C, Ortego-Centeno N, Vonk MC, Coenen M, Riemekasten G, Hunzelmann N, Hesselstrand R, Tan FK, Reveille JD, Assassi S, Garcia-Hernandez FJ, Carreira P, Camps M, Fernandez-Nebro A, Garcia de la Peña P, McNearney T, Draeger H, González-Gay MA, Airo P, Beretta L, Scorza R, Radstake TR, **Mayes MD**, Arnett FC, Martin J. BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians. *Ann Rheum Dis* 2010 April;69(4):700-5. PMID 19815934
107. Gourh P, Agarwal SK, Martin E, Divecha D, Rueda B, Bunting H, Assassi S, Paz G, Shete S, McNearney T, Draeger H, Reveille JD, Radstake TR, Simeon CP, Rodriguez L, Vicente E, Gonzalez-Gay MA, **Mayes MD**, Tan FK, Martin J, Arnett FC. Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations. *J Autoimmun* 2010 Mar;34(2):155-62. PMID 19796918
108. Kallen MA, **Mayes MD**, Kriseman YL, de Achaval SB, Cox VL, Suarez-Almazor ME. The symptom burden index: development and initial findings from use with patients with systemic sclerosis. *J Rheumatol.* 2010 Aug 1;37(8):1692-8. PMID 20516027
109. Khanna D, Hays RD, Maranian P, Seibold JR, Impens A, **Mayes MD**, Clements PJ, Getzug T, Fathi N, Bechtel A, Furst DE. Reliability and validity of the University of California, Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument. *Arthritis Rheum*, 2009 Sept 15;61(9):1257-63. PMID 19714600
110. Arora-Singh RK, Assassi S, Del Junco DL, Arnett FC, Perry M, Irfan U, Sharif R, Mattar T, **Mayes MD**. Autoimmune diseases and autoantibodies in the first degree relatives of patients with systemic sclerosis. *J Autoimmun* 2010 Aug;35(1):52-7. PMID 20223638
111. Radstake TR, Gorlova O, Rueda B, Martin JE, Alizadeh BZ, Palomino-Morales R, Coenen MJ, Vonk MC, Voskuyl AE, Scheurwegh AJ, Broen JC, van Riel PL, van 't Slot R, Italiaander A, Ophoff RA, Riemekasten G, Hunzelmann N, Simeon CP, Ortego-Centeno N, González-Gay MA, González-Escribano MF; Spanish Scleroderma Group, Airo P, van Laar J, Herrick A, Worthington J, Hesselstrand R, Smith V, de Keyser F, Houssiau F, Chee MM, Madhok R, Shiels P, Westhovens R, Kreuter A, Kiener H, de Baere E, Witte T, Padykov L, Klareskog L, Beretta L, Scorza R, Lie BA, Hoffmann-Vold AM, Carreira P, Varga J, Hinchcliff M, Gregersen PK, Lee AT, Ying J, Han Y, Weng SF, Amos CI, Wigley FM, Hummers L, Nelson JL, Agarwal SK, Assassi S, Gourh P, Tan FK, Koeleman BP, Arnett FC, Martin J, **Mayes MD**. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. *Nat Genet.* 2010 May;42(5):426-9. PMID 20383147

112. McNearney TA, Sluka KA, Ahn C, Reveille JD, Fischbach M, **Mayes, MD**. Plasma endogenous enkephalin levels in early systemic sclerosis: clinical and laboratory associations. *Clin Exp Rheum* 2010 Mar-Apr;28(2 Suppl 58):S7-11. PMID 20576209 (NIHMS 326527)
113. Assassi S, Sharif R, Lasky RE, McNearney TA, Estrada-Y-Martin RM, Draeger H, Nair DK, Fritzler MJ, Reveille JD, Arnett FC, **Mayes MD**; GENISOS Study Group. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. *Arthritis Res Ther*. 2010; 12(5):R166. PMID 20813056
114. Assassi S, Reveille JD, Arnett FC, Weisman MH, Ward MM, Agarwal SK, Gourh P, Bhula J, Sharif R, Sampat K, **Mayes MD**, Tan FK. Whole-blood gene expression profiling in ankylosing spondylitis shows upregulation of toll-like receptor 4 and 5. *J Rheumatol*. 2011 Jan;38(1):87-98. PMID 20952467
115. Bodukam V, Hays RD, Maranian P, Furst DE, Seibold JR, Impens A, **Mayes MD**, Clements PJ, Khanna D. Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis. *Rheumatology (Oxford)*. 2011 Feb;50(2):330-4. PMID 20884655 PMCID:
116. Nashid M, Khanna PP, Furst DE, Clements PJ, Maranian P, Seibold J, Postlethwaite AE, Louie JS, **Mayes MD**, Agrawal H, Khanna D; on behalf of the investigators of the D-Penicillamine, human recombinant relaxin and oral bovine type I collagen clinical trials. Gender and ethnicity differences in patients with diffuse systemic sclerosis – analysis from three large randomized clinical trials. *Rheumatology (Oxford)*. 2011 Feb;50(2):335-42. PMID: 20889574
117. Hosing C, Nash R, McSweeney P, Mineishi S, Seibold J, Griffith LM, Shulman H, Goldmuntz E, **Mayes M**, Parikh CR, Crofford L, Keyes-Elstein L, Furst D, Steen V, Sullivan KM. Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States. *Biol Blood Marrow Transplant*. 2011 May;17(5):674-81. PMID: 20708086
118. Matucci-Cerinic M, Denton CP, Furst DE, **Mayes MD**, Hsu VM, Carpentier P, Wigley FM, Black CM, Fessler BJ, Merkel PA, Pope JE, Sweiss NJ, Doyle MK, Hellmich B, Medsger TA Jr, Morganti A, Kramer F, Korn JH, Seibold JR. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. *Ann Rheum Dis*. 2011 Jan;70(1):32-8. PMID 20805294
119. Atamas SP, Luzina IG, Ingels J, Choi J, Wong WK, Furst DE, Clements PJ; Investigators of the Oral Collagen Trial in Scleroderma, Postlethwaite AE. Stimulation with type I collagen induces changes in gene expression in peripheral blood mononuclear cells from patients with diffuse cutaneous systemic sclerosis (scleroderma). *Clin Exp Immunol*. 2010 Sep;161(3):426-35. doi: 10.1111/j.1365-2249.2010.04189.x. PMID: 20529088
120. Nguyen B, **Mayes MD**, Arnett FC, Del Junco D, Reveille JD, Gonzalez EB, Draeger HT, Perry M, Hendiani A, Anand KK, Assassi S. HLA-DRB1*0407 and *1304 are risk

- factors for scleroderma renal crisis. *Arthritis Rheum.* 2011 Feb;63(2):530-4. PMID: 21280007 PMCID: PMC3048905
121. Au K, **Mayes MD**, Maranian P, Clements PJ, Khanna D, Steen VD, Tashkin D, Roth MD, Elashoff R, Furst DE. Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study. *Arthritis Care Res. (Hoboken).* 2010 Dec;62(12):1772-8. Doi: 10.1002/acr.20320. PMID: 20740615
 122. Diaz-Gallo LM, Gourh P, Broen J, Simeon C, Fonollosa V, Ortego-Centeno N, Agarwal S, Vonk MC, Coenen M, Riemekasten G, Hunzelmann N, Hesselstrand R, Tan FK, Reveille JD, Assassi S, García-Hernandez FJ, Carreira P, Camps MT, Fernandez-Nebro A, de la Peña PG, Nearney T, Hilda D, González-Gay MA, Airo P, Beretta L, Scorza R, Herrick A, Worthington J, Pros A, Gómez-Gracia I, Trapiella L, Espinosa G, Castellvi I, Witte T, de Keyser F, Vanthuyne M, **Mayes MD**, Radstake TR, Arnett FC, Martin J, Rueda B. Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis. *Ann Rheum Dis.* 2011 Mar;70(3):454-62. PMID: 21131644 PMCID: PMC3170726
 123. Agarwal SK, Wu M, Livingston CK, Parks DH, **Mayes MD**, Arnett FC, Tan FK. Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts. *Arthritis Res Ther* 2011 Jan 11;13(1):R3 PMID 21223583 PMCID: PMC3241348
 124. Coustet B, Agarwal SK, Gourh P, Guedj M, **Mayes MD**, Dieude P, Wipff J, Avouac J, Hachulla E, Diot E, Cracowski JL, Tiev K, Sibilia J, Mouthon L, Frances C, Amoura Z, Carpentier P, Meyer O, Kahan A, Boileau C, Arnett FC, Allanore Y. Association study of *ITGAM*, *ITGAX* and *CD58* autoimmune risk loci in systemic sclerosis: results from two large European Caucasian cohorts. *J Rheumatol.* 2011 Jun;38(6):1033-8. PMID: 21362770 PMCID: PMC3404507
 125. Sharif R, **Mayes MD**, Nicassio PM, Gonzalez EB, Draeger H, McNearney TA, Estrada-Y-Martin RM, Nair DK, Reveille JD, Arnett FC, Assassi S, GENISOS Study Group. Determinants of work disability in patients with systemic sclerosis: A longitudinal study of the GENISOS cohort. *Semin Arthritis Rheum.* 2011 Aug;41(1):38-47. PMCID: PMC3153604
 126. Sharif R, Fritzler MJ, **Mayes MD**, Gonzalez EB, McNearney TA, Draeger H, Baron M, Canadian Scleroderma Research Group, Furst DE, Khanna DK, del Junco DJ, Molitor JA, Schiopu E, Phillips K, Seibold JR, Silver RM, Simms RW, GENISOS Study Group, Perry M, Rojo C, Charles J, Zhou X, Agarwal SK, Reveille JD, Assassi S, Arnett FC. Anti-fibrillar antibody in African American patients with systemic sclerosis: Immunogenetics, clinical features, and survival analysis. *J Rheumatol.* 2011 Aug;38(8):1622-30. PMCID: PMC3149738
 127. Roth MD, Tseng CH, Clements PJ, Furst DE, Tashkin DP, Goldin JG, Khanna D, Klearup EC, Li N, Elashoff D, Elashoff RE, Scleroderma Lung Study Research Group. Predicting treatment outcomes and responder subsets in scleroderma-

- related interstitial lung disease. *Arthritis Rheum*. 2011 Sep;63(9):2797-808. doi: 10.1002/aart.30438. PMID 21547897
128. Assassi S, Leyva AL, **Mayes MD**, Sharif R, Nair DK, Fischbach M, Nguyen N, Reveille JD, Gonzalez EB, McNearney TA, GENISOS Study Group. Predictors of fatigue severity in early systemic sclerosis: A prospective longitudinal study of the GENISOS cohort. *PLoS One*. 2011;6(10):e26061. PMID: 22022507 PMCID: PMC3193535
129. Chaudhary P, Chen X, Assassi S, Gorlova O, Draeger H, Harper BE, Gonzalez E, McNearney T, Perry M, Arnett FC, **Mayes MD**. Cigarette smoking is not a risk factor for systemic sclerosis. *Arthritis Rheum*. 2011 Oct;63(10):3098-102. doi: 10.1002/art.30492. PMCID: PMC3183145
130. Khanna D, Furst DE, Maranian P, Seibold JR, Impens A, **Mayes MD**, Clements PJ, Getzug T, Hays RD. Minimally important differences of the UCLA scleroderma clinical trial consortium gastrointestinal tract instrument. *J Rheumatol* 2011 Sep;38(9):1920-4. PMID 21724699 PMCID: PMC3368014
131. Khanna D, Kowal-Bielecka O, Khanna PP, Lapinska A, Asch SM, Wenger N, Brown KK, Clements PJ, Getzug T, **Mayes MD**, Medsger TA, Oudiz R, Simms R, Steen V, Maranian P, Furst DE. Quality indicator set for systemic sclerosis. *Clin Exp Rheumatol* 2011;Mar-Apr;29 (2 Suppl 65): S33-9. PMID 21586216 NIHMS ID: NIHMS541716
132. Khanna D, Saggarr R, **Mayes MD**, Abtin F, Clements PJ, Maranian P, Assassi S, Saggarr R, Singh RR, Furst DE. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. *Arthritis Rheum* 2011 Nov;63(11):3540-6. PMCID: PMC3205223
133. Gorlova O, Martin JE, Rueda B, Koeleman BP, Ying J, Teruel M, Diaz-Gallo LM, Broen JC, Vonk MC, Simeon CP, Alizadeh BZ, Coenen MJ, Voskuyl AE, Schuerwegh AJ, van Riel PL, Vanthuyne M, van't Slot R, Italiaander A, Ophoff RA, Hunzelmann N, Fonollosa V, Ortego-Centeno N, Gonzalez-Gay MA, Garcia-Hernandez FJ, González-Escribano MF, Airo P, van Laar J, Worthington J, Hesselstrand R, Smith V, de Keyser F, Houssiau F, Chee MM, Madhok R, Shiels PG, Westhovens R, Kreuter A, de Baere E, Witte T, Padyukov L, Nordin A, Scorza R, Lunardi C, Lie BA, Hoffmann-Vold AM, Palm O, Garcia de la Peña P, Carreira P, Spanish Scleroderma Group; Rodriguez-Rodriguez L, Vicente E, Fonollosa V, Voskuyl AE, Schuerwegh AJ, van Riel P LCM, Vanthuyne M, Houssiau F, Smith V, de Keyser F, Westhovens R, de Baere E, Kreuter A, Witte T, Riemekasten G, Hesselstrand R, Padyukov L, Nordin A, Lie BA, Hoffmann-Vold A-M, Palm Ø, Airo P, Scorza R, Lunardi C, Hunzelmann N, Beretta L, Tan FK, Arnett FC, **Mayes MD**, Martin J. Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. *PLoS Genet*. 2011 Jul;7(7):e1002178. PMID 21779181 PMCID: PMC3136437
134. Carmona FD, Gutala R, Simeón CP, Carreira P, Ortego-Centena N, Vincente-Rabaneda E, García-Hernández FC, García de la Peña P, Fernández-Castro M,

- Martinez-Estupiñán L, Egurbide MV, Tsao BP, Gourh P, Agarwal SK, Assassi S, **Mayes MD**, Arnett FC, Tan FK, Martín J, Spanish Scleroderma Group. Novel identification of the IRF7 region as an anticentromere autoantibody propensity locus in systemic sclerosis. *Ann Rheum Dis*. 2012 Jan;71(1):114-9. PMID 21926187 PMCID: PMC3369428
135. Thombs BD, Jewett LR, Assassi S, Baron M, Bartlett SJ, Maia AC, El-Baalbaki G, Furst DE, Gottesman K, Haythornthwaite JA, Hudson M, Impens A, Korner A, Leite C, **Mayes MD**, Malcarne VL, Motivala SJ, Mouthon L, Nielson WR, Plante D, Poiraudeau S, Poole JL, Pope J, Sauve M, Steele RJ, Suarez-Almazor ME, Taillefer S, van den Ende CH, Arthurs E, Bassel M, Delisle V, Milette K, Leavens A, Razykov I, Khanna D. New directions for patient-centered care in scleroderma: the Scleroderma Patient-centered Intervention Network (SPIN). *Clin Exp Rheumatol*. 2012 Mar-Apr;30(2 Suppl 71):S23-9. PMID 22244687
136. Walker KM, Pope J, Scleroderma Clinical Trials Consortium, Canadian Scleroderma Research Group. Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis. *J. Rheumatol*. 2011 Jul;38(7):1326-8. PMID 21459952
137. Bossini-Castillo L, Martin JE, Broen J, Gorlova O, Simeón CP, Beretta L, Vonk MC, Callejas JL, Castellvi I, Carreira P, García-Hernández FJ, Fernández Castro M, Spanish Scleroderma Group, Coenen MJ, Riemekasten G, Witte T, Hunzelmann N, Kreuter A, Distler JH, Koeleman BP, Voskuyl AE, Schuerwegh AJ, Palm Ø, Hesselstrand R, Nordin A, Airó P, Lunardi C, Scorza R, Shiels P, van Laar JM, Herrick A, Worthington J, Denton C, Tan FK, Arnett FC, Agarwal SK, Assassi S, Fonseca C, **Mayes MD**, Radstake TR, Martin J. A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. *Hum Mol Genet*. 2012 Feb 15;21(4):926-33. PMID 22076442 PMCID: PMC3298110
138. Martin JE, Broen JC, Carmona FD, Teruel M, Simeon CP, Vonk MC, van t' Slot R, Rodriguez-Rodriguez L, Vicente E, Fonollosa V, Ortego-Centeno N, González-Gay MA, García-Hernández FJ, de la Peña PG, Carreira P, Spanish Scleroderma Group, Voskuyl AE, Schuerwegh AJ, van Reil PL, Kreuter A, Witte T, Riemekasten G, Airo P, Scorza R, Lunardi C, Hunzelmann N, Distler JH, Beretta L, van Laar J, Chee MM, Worthington J, Herrick A, Denton C, Tan FK, Arnett FC, Assassi S, Fonseca C, **Mayes MD**, Radstake TR, Koeleman BP, Martin J. Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. *Hum. Mol. Genet*. 2012 Jun 15;21(12):2825-35. PMID 22407130 PMCID: PMC3368627
139. Bae S, Saggat R, Bolster MB, Chung L, Csuka ME, Derk C, Domsic R, Fischer A, Frech T, Goldberg A, Hinchcliff M, Hsu V, Hummers L, Schiopu E, **Mayes MD**, McLaughlin V, Molitor J, Naz N, Furst DE, Maranian P, Steen V, Khanna D. Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: Results

- from the PHAROS registry. *Ann Rheum Dis.* 2012 Aug;71(8):1335-42. PMID 22307943
140. Wu M, Schneider DJ, **Mayes MD**, Assassi S, Arnett FC, Tan FK, Blackburn MR, Agarwal SK. Osteopontin in systemic sclerosis and its role in dermal fibrosis. *J Invest Dermatol.* 2012 Jun;132(6):1605-14. Doi: 10.1038/jid.2012.32. PMID 22402440 PMCID: PMC3365548
141. Merkel PA, Silliman NP, Clements PJ, Denton CP, Furst DE, **Mayes MD**, Pope JE, Polisson RP, Streisand JB, Seibold JR; for the Scleroderma Clinical Trials Consortium. Patterns and predictors of change in outcome measures in clinical trials in scleroderma. An individual patient meta-analysis of 629 subjects with diffuse cutaneous scleroderma. *Arthritis Rheum.* 2012 Oct;64(10):3420-9. Doi: 10.1002/art.34427. PMID 22328195
142. Coustet B, Bouaziz M, Dieudé P, Guedj M, Bossini-Castillo L, Agarwal S, Radstake T, Martin J, Gourh P, Elhai M, Koumakis E, Avouac J, Ruiz B, **Mayes M**, Arnett F, Hachulla E, Diot E, Cracowski JL, Tiev K, Sibilia J, Mouthon L, Frances C, Amoura Z, Carpentier P, Cosnes A, Meyer O, Kahan A, Boileau C, Chiocchia G, Allanore Y. Independent replication and metaanalysis of association studies establish TNFSF4 as a susceptibility gene preferentially associated with the subset of anticentromere-positive patients with systemic sclerosis. *J Rheumatol.* 2012 May;39(5):997-1003. PMID 22422496 PMCID: PMC3687343
143. Sharif R, **Mayes MD**, Tan FK, Gorlova OY, Hummers LK, Shah AA, Furst DE, Khanna D, Martin J, Bossini-Castillo L, Gonzalez EB, Ying J, Draeger HT, Agarwal SK, Reveille JD, Arnette FC, Wigley FM, Assassi S. IRF5 polymorphism predicts prognosis in patients with systemic sclerosis. *Ann Rheum Dis.* 2012 Jul;71:1197-202. PMID 22440820 PMCID: PMC3375372
144. Bossini-Castillo L, Martin JE, Broen J, Simeon CP, Beretta L, Gorlova OY, Vonk MC, Ortego-Centeno N, Espinosa G, Carreira P, García de la Peña P, Oreiro N, Román-Ivorra JA, Castillo MJ, González-Gay MA, Sáez-Comet L, Castellví I, Schuerwegh AJ, Voskuyl AE, Hoffmann-Vold AM, Hesselstrand R, Nordin A, Lunardi C, Scorza R, van Laar JM, Shiels PG, Herrick A, Worthington J, Fonseca C, Denton C, Tan FK, Arnett FC, Assassi S, Koeleman BP, **Mayes MD**, Radstake TR, Martin J., the Spanish Scleroderma Group. Confirmation of TNIP1 but not RHOB and PSORS1C1 as systemic sclerosis risk factor in a large independent replication study. *Ann Rheum Dis.* 2013 Apr;72(4):602-7. Doi: 10.1136/annrheumdis-2012-201888. PMID 22896740 PMCID: PMC3887516
145. Merz EL, Malcarne VL, Roesch SC, Sharif R, Harper BE, Draeger HT, Gonzalez EB, Nair DK, McNearney TA, Assassi S, **Mayes MD**. Measuring illness behavior in patients with systemic sclerosis. *Arthritis Care Res (Hoboken).* 2013 Apr;65(4):585-93. doi: 10.1002/acr.21874. PMID 23097280 PMCID: PMC3578093
146. Liu X, **Mayes MD**, Tan FK, Wu M, Reveille JD, Harper BE, Draeger HT, Gonzalez B, Assassi S. Correlation of interferon-inducible chemokine plasma levels with

- disease severity in systemic sclerosis. *Arthritis Rheum.* 2013 Jan;65(1):226-35. doi: 10.1002/art.37742. PMID 23055137 PMCID: PMC3687352
147. Walker KM, Pope J, Scleroderma Clinical Trials Consortium (SCTC), Canadian Scleroderma Research Group (CSRG). Treatment of systemic sclerosis complications: what to use when first-line treatment fails – a consensus of systemic sclerosis experts. *Semin Arthritis Rheum.* 2012 Aug;42(1):42-55. PMID 22464314
148. Diaz-Gallo LM, Simeon CP, Broen JC, Orego-Centeno N, Beretta L, Vonk MC, Carreira PE, Vargas S, Román-Ivorra JA, González-Gay MA, Tolosa C, López-Longo FJ, Espinosa G, Vicente EF, Hesslestrand R, Riemekasten G, Witte T, Distler JH, Voskuyl AE, Schuerwegh AJ, Shiels PG, Nordin A, Padyukov L, Hoffmann-Vold AM, Scorza R, Lunardi C, Airó P, van Laar JM, Hunzelmann N, Gathof BS, Kreuter A, Herrick A, Worthington J, Denton CP, Zhou X, Arnett FC, Fonseca C, Koeleman BP, Assassi S, Radstake TR, **Mayes MD**, Martin J, the Spanish Scleroderma Group. Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility. *Ann Rheum Dis.* 2013 Jul;72(7):1233-8. PMID 23172754 PMCID: PMC3887514
149. Wang J, Assassi S, Guo G, Tu W, Wu W, Yang L, Xiao R, Zhao Y, Chu H, Liu J, Ma Y, Kim SJ, Jin L, **Mayes MD**, Zou H, Zhou X. Clinical and serological features of systemic sclerosis in a Chinese cohort. *Clin Rheumatol.* 2013 May;32(5):617-21. PMID 23271609 PMCID PMC3734856
150. de Achaval S, Kallen MA, **Mayes MD**, Lopez-Olivo MA, Suarez-Almazor ME. Use of the patient generated index in systemic sclerosis. *J Rheumatol* 2013 Aug;40(8):1337-43. PMID 23772081. PMCID: PMC3888061
151. Elhaj M, Charles J, Pedroza C, Liu X, Zhou X, Estrada-Y-Martin RM, Gonzalez E, Lewis DE, Draeger HT, Kim S, Arnett FC, **Mayes MD**, Assassi S. Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis? *J Rheumatol.* 2013 Jul;40(7):1114-20. PMID 23588945 PMCID PMC3728890
152. Liu X, **Mayes MD**, Pedroza C, Draeger HT, Gonzalez EB, Harper BE, Reveille JD, Assassi S. Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis? *Arthritis Care Res.* 2013 Aug;65(8):1375-80. Doi: 10.1002/acr.21968. PMID 23401350 PMCID PMC3816494
153. Carmona FD, Cénit MC, Diaz-Gallo LM, Broen JC, Simeón CP, Carreria PE, Callejas-Rubio JL, Fonollosa V, López-Longo FJ, González-Gay MA, Hunzelmann N, Riemekasten G, Witte T, Kreuter A, Distler JH, Madhok R, Shiels P, van Laar JM, Schuerwegh AJ, Vonk MC, Voskuyl AE, Fonseca C, Denton CP, Herrick A, Worthington J, Arnett FC, Tan FK, Assassi S, Radstake TR, **Mayes MD**, Martin J; Spanish Scleroderma Group. New insight on the Xq28 association with systemic sclerosis. *Ann Rheum Dis* 2013 Dec 1;72(12):2032-8. Doi: 10.1136/annrheumdis-2012-202742. PMID 23444193 PMCID PMC3818491

154. Hung EW, **Mayes MD**, Sharif R, Assassi S, Machicao VI, Hosing C, St Clair EW, Furst DE, Khanna D, Forman S, Mineishi S, Phillips K, Seibold JR, Bredeson C, Csuka ME, Nash RA, Wener MH, Simms R, Ballen K, Leclercq S, Storek J, Goldmuntz E, Welch B, Keyes-Elstein L, Castina S, Crofford LJ, McSweeney P, Sullivan KM. Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial. *J. Rheumatol.* 2013 Apr 40(4):455-60. Doi: 10.3899/jrheum.121087. PMID 23418384. PMCID:PMC3652008
155. Yi L, Wang JC, Guo XJ, Gu YH, Tu WZ, Guo G, Yang L, Xiao R, Yu L, **Mayes MD**, Assassi S, Zou HJ, Zhou XD. *STAT4* is a genetic risk factor for systemic sclerosis in Chinese population. *Int. J. Immunopathol. Pharmacol.* 2013 Apr-Jun;26(6):473-8. PMID: 23755762
156. Martin JE, Assassi S, Diaz-Gallo LM, Broen JC, Simeón CP, Castellvi I, Vicente-Rabanda E, Fonollosa V, Ortego-Centeno N, González-Gay MA, Espinosa G, Carreira P; Spanish Scleroderma Group; SLEGEM consortium; U.S. Scleroderma GWAS group; BIOLUPUS, Camps M, Sabio JM, D'Alfonso S, Vonk MC, Voskuyl AE, Schuerwegh AJ, Kreuter A, Witte T, Riemakasten G, Hunzelmann N, Airo P, Beretta L, Scorza R, Lunardi C, vanLaar JM, Chee MM, Worthington J, Herrick A, Denton C, Fonseca C, Tan FK, Arnett F, Zhou X, Reveille JD, Gorlova O, Koeleman BP, Radstake TR, Vyse T, **Mayes MD**, Arlacón-Requelme ME, Martin J. A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci, *Hum Molec Genet* 2013 Oct 1;22(19):4021-9. Doi: 10.1093/hmg/ddt248. PMID: 23740937 PMCID: PMC3766185
157. Kwakkenbos L, Jewett LR, Baron M, Bartlett SJ, Furst D, Gottesman K, Khanna D, Malcarne VL, **Mayes MD**, Mouthon L, Poiraudreau S, Sauve M, Nielson WR, Poole JL, Assassi S, Boutron I, Ells C, van den Ende CHM, Hudson M, Impens A, Körner A, Leite C, Costa Maia A, Mendelson C, Pope J, Steele RJ, Suarez-Almazor ME, Ahmed S, Coronado-Montaya S, Delisle VC, Gholizadeh S, Jang Y, Levis B, Millette K, Mills SD, Razykov I, Sobel RM, Thombs BD. The Scleroderma Patient-centered Intervention Network (SPIN) cohort: Protocol for a cohort multiple randomized controlled trial (mcRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context. *BMJOpen* 2013 Aug 7;3(8). doi:pii: e003563. 10.1136/bmjopen-2013-003563. PMID: 23929922 PMCID: PMCID3740254
158. Zhou XD, Yi L, Guo XJ, Chen E, Zou HJ, Jin L, **Mayes MD**, Assassi S, Wang JC. Association of HLA-DQB1*0501 with scleroderma and its clinical features in Chinese population. *Int J Immunopathol Pharmacol.* 2013 Jul-Sept;26(3):747-51. PMID: 24067471 PMCID: PMC3887513
159. Assassi S, Wu M, Tan FK, Chang J, Graham TA, Furst DE, Khanna D, Charles J, Ferguson EC, Feghali-Bostwick C, **Mayes, MD**. Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis. *Arthritis Rheum* 2013 Nov;65(11):2917-27. Doi: 10.1002/art.38101. PMID: 23897225 PMCID: PMC3898704

160. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, **Mayes MD**, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Müller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Csuka EM, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European League against Rheumatism collaborative initiative. *Arthritis Rheum.* 2013 Nov;65(11):2737-47. PMID: 24122180 PMID: PMC3930146
161. Merz EL, Malcarne VL, Assassi S, Nair DK, Graham TA, Yellman BP, Estrada y Martin R, **Mayes MD**. Biopsychosocial typologies of pain in a cohort of patients with systemic sclerosis. *Arthritis Care Res (Hoboken).* 2014 Apr;66(4):567-74. Doi: 10.1002/acr.22171. PMID 24106135 PMID: PMC3960366
162. López-Isac E, Bossini-Castillo L, Simeon CP, Egurbide MV, Alegre-Sancho JJ, Callejas JL, Roman-Ivorra JA, Freire M, Beretta L, Santaniello A, Airó P, Lunardi C, Hunzelmann N, Riemekasten G, Witte T, Kreuter A, Distler JHW, Schuerwegh AJ, Vonk MC, Voskuyl AE, Shiels PG, van Laar JM, Fonseca C, Denton C, Herrick A, Worthington J, Assassi S, Koeleman BP, **Mayes MD**, Radstake TRDJ, Martin J. A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility. *Arthritis Res Ther.* 2014 Jan 9;16(1):R6 PMID 24401602
163. Van Bon L, Affandi AJ, Broen J, Christmann RB, Marijnissen RJ, Stawski L, Farina GA, Stifani G, Mathes AL, Cossu M, York M, Collins C, Wenink M, Huijbens R, Hesselstrand R, Saxne T, DiMarzio M, Wuttge D, Agarwal SK, Reveille JD, Assassi S, **Mayes M**, Deng Y, Drenth JPH, van der Graaf J, den Heijer M, Kallenberg CGM, Bijl M, Loof A, van den Berg WB, Joosten LAP, Smith V, de Keyser F, Scorza R, Lunardi C, van Riel PLCM, Vonk M, van Heerde W, Meller S, Homey B, Beretta L, Roest M, Trojanowska M, Lafyatis R, Radstake TRDJ. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. *New Eng J Med.* 2014 Jan 30;370(5):433-43. PMID: 24350901 PMID: PMC4040466
164. Dharamsi JW, Victor S, Aguwa N, Ahn C, Arnett F, **Mayes MD**, Jacobe H. Morphea in adults and children cohort III: Nested case-control study – the clinical significance of autoantibodies in morphea. *JAMA Dermatol.* 2013 Oct;149(10):1159-65. doi: 10.1001/jamadermatol.2013.4207. PMID: 23925398 PMID: PMC4153681
165. Draeger HT, Assassi S, Sharif R, Gonzalez EM, Harper B, Arnette FC, Manzoor A, Lange RA, **Mayes MD**. Right bundle branch block: A predictor of mortality in early systemic sclerosis. *PLoS One.* 2013 Oct 31;8(10):e78808. PMID: PMC3814983
166. Wu M, Pedroza M, Lafyatis R, George AT, **Mayes MD**, Assassi S, Tan FK, Brenner MB, Agarwal SK. Identification of cadherin-11 as a mediator of dermal fibrosis

- and possible role in systemic sclerosis. *Arthritis Rheumatol.* 2014 Apr;66(4):1010-21. PMID 24757152
167. **Mayes MD**, Bossini-Castillo L, Gorlova O, Martin JE, Zhou X, Chen WV, Assassi S, Ying J, Tan K, Arnett FC, Reveille JD, Guerra S, Teruel M, Carmona FD, Gregersen PK, Lee AT, López-Isac E, Ochoa E, Carreira P, Simeón CP, Castellvi I, González-Gay MA, the Spanish Scleroderma Group, Koeleman BP, Zhernakova A, Padyukov L, Alarcón-Requielme M, Wijmenga C, Brown M, Beretta L, Riemekasten G, Witte T, Hunzelmann N, Kreuter A, Distler JHW, Voskuyl AE, Scherwegh AJ, Hesselstrand R, Nordin A, Airó P, Lunardi C, Shiels P, van Laar PM, Herrick A, Worthington J, Denton C, Wigley FM, Hummers LK, Varga J, Hinchcliff ME, Baron M, Hudson M, Pope JE, Furst ED, Khanna D, Phillips K, Schioppa E, Segal BM, Molitor JA, Silver RM, Steen FD, Simms RW, Lafyatis RA, Fessler BJ, Frech TM, Alkassab F, Docherty P, Kaminska E, Khalidi N, Jones HN, Markland J, Robinson D, Broen J, Radstake TRDJ, Fonseca C, Martin J. ImmunoChip analysis identifies multiple susceptibility loci for systemic sclerosis. *Am J Hum Genet.* 2014 Jan 2;94(1):47-61. Doi: 10.1016/j.ajhg.2013.12.002. PMID 24387989 PMCID: PMC3882906
168. Baron M, Chung L, Gyger G, Hummers L, Khanna D, **Mayes MD**, Pope JE, Shah AA, Steen VD, Steele R, Tatibouet S, Herrick A, Muller-Ladner U, Hudson M. Consensus opinion of a North American working group regarding the classification of digital ulcers in systemic sclerosis. *Clin Rheum.* 2014 Feb; 13(2):207-14. PMID: 24357325
169. Hudson M, Baron M, Tatibouet S, Furst DE, Khanna D; International Scleroderma Renal Crisis Study Investigators. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis—results from the International Scleroderma Renal Crisis Survey. *Semin Arthritis Rheum.* 2014 Apr;43(5):666-72. doi: 10.1016/j.semarthrit.2013.09.008. PMID:24176729
170. Hsu VM, Chung L, Hummers LK, Wigley F, Simms R, Bolster M, Silver R, Fischer A, Hinchcliff ME, Varga J, Goldberg AZ, Derk CT, Schioppa E, Khanna D, Shapiro LS, Domsic RT, Medsger T, **Mayes MD**, Furst D, Csuka ME, Molitor JA, Alkassab F, Steen VD. Development of pulmonary hypertension in a high risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. *Semin Arthritis Rheum.* 2014 Aug;44(1):55-62. PMID: 24709277.
171. Johnson SR, Naden RP, Fransen J, van den Hoogen F, Pope JE, Baron M, Tyndall A, Matucci-Cerinic M, Denton CP, Distler O, Gabrielli A, van Laar JM, **Mayes M**, Steen V, Seibold JR, Clements P, Medsger TA Jr, Carreira PE, Riemekasten G, Chung L, Fessler BJ, Merkel PA, Silver R, Varga J, Allanore Y, Mueller-Ladner U, Vonk MC, Walker UA, Cappelli S, Khanna D. Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. *J Clin Epidemiol.* 2014 Jun;67(6):706-14. PMID: 24721558 PMCID: PMC4134523

172. Wang J, Guo X, Yi L, Guo G, Tu W, Wu W, Yang L, Xiao R, Li Y, Chu H, He D, Jin L, **Mayes MD**, Zou H, Zhou X. Association of HLA-DPB1 with scleroderma and its clinical features in Chinese population. *PLoS One*. 2014 Jan 31;9(1):e87363. PMID: 24498086 PMCID: PMC3909094
173. Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankel S, Oddis CV, Denton CP, Fischer A, Kowal-Bielecka OM, LeSage D, Merkel PA, Phillips K, Pittrow D, Swigris J, Antoniou K, Baughman RP, Castellino FV, Christmann RB, Christopher-Stine L, Collard HR, Cottin V, Dannoff S, Highland KB, Hummers L, Shah AA, Kim DS, Lynch DA, Miller FW, Proudman SM, Richeldi L, Ryu JH, Sandorfi N, Sarver C, Wells AU, Strand V, Matteson EL, Brown KK, Seibold JR; CTD-ILD Special Interest Group. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. *Thorax*. 2014 May;69(5):436-44. 10.1136/thoraxjnl-2013-204202. PMID: 24368713 PMCID: PMC3395282
174. Maverakis E, Patel F, Kronenberg DG, Chung L, Fiorentino D, Allanore Y, Guiducci S, Hesselstrand R, Hummers LK, Duong C, Kahaleh B, Macgregor A, Matucci-Cerinic M, Wollheim FA, **Mayes MD**, Gershwin ME. International consensus criteria for the diagnosis of Raynaud's phenomenon. *J Autoimmun*. 2014 Feb-Mar;48-49:60-5. PMID: 24491823 PMCID: PMC4018202
175. Saketkoo LA, Mittoo S, Frankel S, LeSage D, Sarver C, Phillips K, Strand V, Matteson EL; OMERACT Connective Tissue Disease-Interstitial Lung Diseases Working Group; OMERACT Connective Tissue Disease-Interstitial Lung Diseases Working Group. Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases. *J Rheumatol*. 2014 Apr;41(4):792-8. doi: 10.3899/jrheum.131251. PMID: 24488412
176. Wiese AB, Berrocal VJ, Furst DE, Seibold JR, Merkel PA, **Mayes MD**, Khanna D. Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis. *Arthritis Care Res (Hoboken)*. 2014 Nov;66(11):1731-9. doi: 10.1002/acr.22339. PMID:24692361
177. López-Isac E, Bossini-Castillo L, Guerra S, Assassi S, Zhou X, PilarSimeón C, Ortego-Centeno N, Castellví I, Carreira P, Gorlova O, Beretta L, Santaniello A, Lunardi C, Hesselstrand R, Nordin A, Riemekasten G, Witte T, Hunzelmann N, Kreuter A, Distler JH, Voskuyl AE, deVries-Bouwstra J, Koeleman BP, Herrick A, Worthington J, Denton C, Fonseca C, Radstake TR, **Mayes MD**, Martin J; the Spanish Scleroderma Group. Identification of IL12RB1 as a novel systemic sclerosis susceptibility locus. *Arthritis Rheumatol*. 2014 Dec; 66(12):3521-3. PMID: 25199642 PMCID: PMC4245383
178. Kottyan LC, Zoller EE, Bene J, Lu X, Kelly JA, Rupert AM, Lessard CJ, Vaughn SE, Marion M, Weirauch MT, Namjou B, Adler A, Rasmussen A, Glenn S, Montgomery CG, Hirschfield GM, Xie G, Coltescu C, Amos C, Li H, Ice JA, Nath SK, Mariette X; Simon Bowman for UK primary Sjögren's syndrome registry, Rischmueller M, Lester

- S, Brun JG, Gøransson LG, Harboe E, Omdal R, Cunninghame-Graham DS, Vyse T, Miceli-Richard C, Brennan MT, Lessard JA, Wahren-Herlenius M, Kvarnström M, Illei GG, Witte T, Jonsson R, Ericksson P, Nordmark G, Ng W-F for UK primary Sjögren's syndrome registry, Anaya JM, Rhodus NL, Segal BM, Merrill JT, James JA, Guthridge JM, Scofield RH, Alarcon-Riquelme M, Bae SC, Boackle SA, Criswell LA, Gilkeson G, Kamen DL, Jacob CO, Kimberly R, Brown E, Edberg J, Alarcón GS, Reveille JD, Vilá LM, Petri M, Ramsey-Goldman R, Freedman BI, Niewold T, Stevens AM, Tsao BP, Ying J, **Mayes MD**, Gorlova OY, Wakeland W, Radstake T, Martin E, Martin J, Simonovitch K, Moser Sivils KL, Gaffney PM, Langefeld CD, Harley JB, Kaufman KM. The IRF5-TNPO3 association with systemic lupus erythematosus (SLE) has two components that other autoimmune disorders variably share. *Hum Mol Genet.* 2015 Jan 15;24(2):582-96. PMID: 25205108 PMCID: PMC4275071
179. He D, Wang J, Yi L, Guo X, Guo S, Guo G, Tu W, Wu W, Yang L, Xiao R, Li Y, Chu H, Lai S, Jin L, Zou H, Reveille JD, Assassi S, **Mayes MD**, Zhou X. Association of the HLA-DRB1 with scleroderma in Chinese population. *PLoS One.* 2014 Sept;9(9):e106939. PMID: 25184637. PMCID: PMC4153724
180. Wang J, Yi L, Guo X, He D, Li H, Guo G, Wang Y, Zou H, Gu Y, Tu W, Wu W, Yang L, Xiao R, Lai S, Assassi S, **Mayes MD**, Zhou X. Lack of association of the CD247 SNP rs2056626 with systemic sclerosis in Han Chinese. *Open Rheumatol J.* 2014 Oct 2;8:43-5. PMID 25317213 PMCID: PMC4192828
181. Salazar GA, Assassi S, Wigley F, Hummers L, Varga J, Hinchcliff M, Khanna D, Schioppa E, Phillips K, Furst DE, Steen V, Baron M, Hudson M, Taillefer SS, Pope J, Jones N, Docherty P, Khalidi NA, Robinson D, Simms RW, Silver RM, Frech TM, Fessler BJ, Molitor JA, Fritzler MJ, Segal BM, Al-Kassab F, Perry M, Yang J, Zamanian S, Reveille JD, Arnett FC, Pedroza C, **Mayes MD**. Antinuclear antibody-negative systemic sclerosis. *Semin Arthritis Rheum.* 2014 Nov 28. [Epub ahead of print]
182. Wallace B, Kafaja S, Furst DE, Berrocal VJ, Merkel PA, Seibold JR, Mayes MD, Khanna D. Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis. *Rheumatology (Oxford).* 2015 Feb 9. Pii:keu456. [Epub ahead of print]
183. Ochoa E, Martin JE, Assassi S, Beretta L, Carreira P, Simeón CP, Koumakis E, Dieude P, Allanore Y, García-Hernández FJ, Espinosa G, Castellvi I, Trapiella JL, Rodriguez L, González-Gay MA, Egurbide MV, Sáez L, Callejas-Rubio JL, Vargas JA, Hunzelmann N, Riemekasten G, Witte T, Distler JHW, Kreuter A, Lunardi C, Santaniello A, Tan FK, Arnett FC, Shiels PG, Herrick A, Worthington J, Vonk MC, Koeleman BP, Radstake TRDJ, **Mayes MD**, Martin J. Confirmation of CCR6 as a risk factor for antitopoisomerase I antibodies in systemic sclerosis. *Submitted to Arthritis Res Ther.*, 2014
184. Wu M, Assassi S, Salazar GA, Pedroza C, Gorlova OY, Chen WV, Charles J, Taing ML, Wigley FM, Hummers LK, Shah AA, Hinchcliff M, Khanna D, Schioppa E, Phillips

- K, Furst DE, Steen V, Baron M, Hudson M, Zhou X, Pope J, Jones N, Docherty P, Khalidi NA, Robinson D, Simms RW, Silver RM, Frech TM, Fessler BJ, Fritzler MJ, Molitor JA, Segal BM, Movahedian M, Martin J, Varga J, Mayes MD. Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis. *Submitted to Arthritis Rheum* 2014.
185. Wodkowski M, Hudson M, Proudman S, Walker J, Stevens W, Nikpour M, Assassi S, Mayes MD, Tatibouet S, Wang M, Baron M, Fritzler MJ. Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects. *Submitted to Arthritis Res Ther.*, 2014.
186. Assassi S, Swindell W, Wu M, Tan FK, Khanna D, Furst DE, Tashkin D, Jahan-Tigh R, Mayes MD, Gudjonsson J, Chang JT. Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis. *Arthritis Rheum. Submitted revision* 2015.

C. INVITED ARTICLES, REVIEWS AND LETTERS TO THE EDITOR

1. **Mayes MD.** Scleroderma Epidemiology. *Rheumatic Disease Clinics of North America* 22:751-764, 1996.
2. **Mayes MD.** Epidemiology of systemic sclerosis and related diseases. *Curr Opin Rheumatol.* 1997;9:557-561.
3. **Mayes MD.** Classification and epidemiology of scleroderma. *Semin Cutan Med Surg.* 1998;17:22-26.
4. **Mayes MD.** Epidemiologic studies of environmental agents and systemic autoimmune disease. *Environ Health Perspect.* 107:743-748,1999.
5. **Mayes MD.** Photopheresis and autoimmune diseases. *Rheum Dis Clin North Am*26:75-82, 2000.
6. **Mayes MD.** Scleroderma. *Pediatr Dermatol.* 17:75-83, 2000.
7. Miller FW, Hess EV, Clauw DJ, Hertzman PA, Pincus T, Silver RM, **Mayes MD**, Varga J, Medsger Jr. T, and Love LA. Approaches for identifying and defining environmentally associated rheumatic disorders. *Arthritis Rheum* 43:243-249, 2000.
8. **Mayes MD.** The establishment and utility of a population-based registry to understand the epidemiology of systemic sclerosis. *Curr Rheumatol Rep* 2:512-516, 2000.
9. **Mayes, MD.** Endothelin and endothelin receptor antagonists in systemic rheumatic disease. *Arthritis Rheum* 48(5):1190-9,2003.
10. **Mayes MD.** Scleroderma epidemiology. *Rheum Dis Clin North Am* 29:239-54, 2003.
11. Steen VD, **Mayes MD**, Merkel PA. Assessment of kidney involvement. Supplement 29: The assessment of the patient with systemic sclerosis. *Clin Exp Rheumatol* 21: S29-31, 2003.

12. Assassi S, **Mayes MD**. The genetics of scleroderma: What every rheumatologist should know. *Scleroderma Care Res* 1:3-11, 2004.
13. Griffith LM, Pavletic SZ, Tyndall A, Bredeson CN, Bowen JD, Childs RW, Gratwohl A, vanLaar JM, **Mayes MD**, Martin R, McSweeney PA, Muraro PA, Openshaw H, Saccardi R, Sandmaier BM, Forman SJ, Nash RA on behalf of the workshop participants. Feasibility of allogeneic stem cell transplantation for autoimmune disease: Position statement from a NIAID and NCI-sponsored international workshop. *Biol Blood Marrow Transplant* 11:862-70, 2005.
14. **Mayes MD**. Race, Scleroderma, and Survival: Why is there a difference? *J Rheumatol* (Editorial)32:1873-4, 2005.
15. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch C, Kremers HM, Kwoh CK, Liang MH, **Mayes MD**, Pillemer SR, Reveille JD for the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I. *Arthritis Rheum* 58:15-25,2008 Jan.
16. Alkassab F, **Mayes MD**. The Genetics and Genomics of SSc. An Update and Review. 2007 *Curr Rheum Rev* 3:287-96, 2007.
17. **Mayes MD**, Trojanowska M. Genetic factors in systemic sclerosis. *Arthritis Res Ther*. 9 suppl 2:S5, 2007.
18. Alkassab F, Gourh P, Tan F, Arnett F, **Mayes M**. Comment on: An allograft inflammatory factor 1 (AIF1) single nucleotide polymorphism (SNP) is associated with anticentromere antibody positive systemic sclerosis: reply. *Rheumatology* (Oxford). 2008 Mar 7.
19. Gourh P, **Mayes MD**, Arnett FC. CTGF polymorphism associated with systemic sclerosis. *N Engl J Med*. 2008 Jan 17;358(3):308-9.
20. Nguyen B, Assassi S, Arnett FC, **Mayes MD**. Association of RNA polymerase III antibodies with scleroderma renal crisis. (Letter to the Editor) *J Rheumatol* 2010 May;37(5):1068. PMID:20439528
22. Barnes J, **Mayes MD**. Epidemiology of systemic sclerosis: Incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. *Curr Opin Rheumatol*. 2012 Mar;24(2):165-70. PMID: 22269658
23. **Mayes MD**. The genetics of scleroderma: looking into the postgenomic era. *Curr Opin Rheumatol*. 2012 Nov;24(6):677-84. Doi:10.1097/BOR.0b013e328358575b. PMID: 23026857
24. Assassi S, Radstake TRDJ, **Mayes MD**, Martin J. Genetics of scleroderma: implications for personalized medicine? *BMC Med*. 2013 Jan 11;11(1):9. PMID: 23311619
25. Assassi S, **Mayes MD**. What does global gene expression profiling tell us about the pathogenesis of systemic sclerosis? *Curr Opin Rheumatol*. 2013 Nov;25(6):686-91. Doi: 10.1097/01.bor.0000434672.77891.41. PMID: 24061076
26. Wu, M, **Mayes MD**. Insights into the genetic basis of systemic sclerosis: Immunity in human disease and SSc mouse models. *Adv Genomics Genet*. 2014 *In press*.

D. CHAPTERS

1. Krakauer RS, **Mayes MD**, and Clough JD. Assays of suppression of lymphocyte function in SLE patients and first order relatives in Mechanisms of Lymphocyte Activation. Proceedings of the 14th International Leucocyte Conference held in Heidelberg, F.R.G., June 7-11, 1981. Klaus Resch Holger Kirchner, Editors. Elsevier/North Holland Biomedical Press.
2. **Mayes MD**, Cathcart M, Dustoor M, et al. The role of immunopathogenesis of progressive systemic sclerosis. Proceedings of the Second International Conference on Progressive Systemic Sclerosis, Austin, TX, October 20, 1982.
3. **Mayes MD**, Reveille JD. Epidemiology, Demographics, and Genetics. In Clements P and Furst D (ed): Systemic Sclerosis, 2nd edition. Philadelphia:Lippincott Williams & Wilkins, 2004.
4. MacNeil MC, **Mayes MD**. Systemic Sclerosis: Assessing disease activity and outcome in scleroderma. In Hochberg, Silman, Weinblatt and Weisman (ed): Rheumatology 4e. Elsevier Limited, 2007.
5. **Mayes, MD**. Systemic Sclerosis: Clinical Aspects. In Klippel JH, Stone JH, Crofford LJ and White PH (ed): Primer on the Rheumatic Diseases, 13th Edition, Atlanta, Springer, 2008.
6. Assassi S, **Mayes MD**. Epidemiology and Classification of Scleroderma. In Hochberg, Silman, Weinblatt and Wiesman (ed): Rheumatology 5e. Elsevier Limited, 2009.
7. Barnes J, **Mayes MD**. Epidemiology of Systemic Sclerosis. In Varga, Denton, Wigley(ed): Scleroderma from Pathogenesis to Comprehensive Management. Springer, 2011.
8. **Mayes, MD**. Comprehensive Approach to Care of the SSc Patient. In Varga, Denton, Wigley (ed): Scleroderma from Pathogenesis to Comprehensive Management. Springer, 2011.
9. **Mayes MD**, Assassi S. Sclerodactyly and Raynaud's Phenomenon in a Patient Who has Primary Biliary Cirrhosis. In Silver, Denton (ed): Case Studies in Systemic Sclerosis. Springer, 2011.

E. BOOKS

1. **Mayes MD**. The Scleroderma Book. New York: Oxford University Press, 2nd edition 2005
2. **Mayes MD** (Ed). A Visual Guide to Scleroderma and Approach to Treatment. New York: Springer Science+Business Media, 2014.

F. OTHER PROFESSIONAL COMMUNICATIONS

PRESENTATIONS International and National meetings:

- a. Invited speaker, The Science and Politics of Women's Health in America, WSU, Detroit, May 1993,
- b. Invited speaker, "Environmentally Associated Connective Tissue Disease" (EACTD) session, American College of Rheumatology national meeting, Orlando, FL, October 21, 1996.
- c. Moderator, "Raynaud's Phenomenon and Scleroderma" session, American College of Rheumatology (ACR) national meeting, Washington, DC, November 8-12, 1997.
- d. Invited speaker, NIH/NIAMS workshop on Atypical Rheumatic Diseases and Silicone Breast Implants, April 17, 1997, Bethesda, MD.
- e. Invited speaker, NIH/NIAMS conference on "Emerging Opportunities in Scleroderma Research," Bethesda, MD, December 8-9, 1997.
- f. Invited speaker, NIH/NIAMS/NIAMS workshop on Environmental Agents and Autoimmune Diseases, Research Triangle Park, NC, September 1-3, 1998.
- g. Invited panel member, NIH/NIAMS workshop on Stem Cell Transplants in Auto-Immune Diseases, Bethesda, MD, September 11, 1998.
- h. Invited speaker, First International Conference on the Mammalian Centromere, Taichung, Taiwan, October 4, 1998.
- i. Invited speaker, Meet the Professor Sessions on Scleroderma, American College of Rheumatology national meeting, San Diego, CA, November 7-12, 1998.
- j. Invited speaker, Society for Pediatric Dermatology, 1999 Annual Meeting, Thompsonville, MI, July 20-23, 1999.
- k. Johns Hopkins University Department of Rheumatology Grand Rounds, "Environmental Triggers in Scleroderma," Baltimore, MD, September 17, 1999.
- l. Invited speaker, Meet the Professor Sessions on Scleroderma, American College of Rheumatology national meeting, Boston, MA, November 13-17, 1999.
- m. Invited speaker, International Scleroderma Biannual Workshop, Keble College, Oxford, UK July 29 – August 2, 2000.
- n. Invited speaker, Meet the Professor Sessions on Scleroderma, American College of Rheumatology national meeting, Philadelphia, PA, October 29-November 3, 2000.
- o. Scleroderma: A Treatable Disease. Einstein School of Medicine/Montefiore Medical Center Rheumatology Grand Rounds, Bronx, NY, October 26, 2001.
- p. Scleroderma: A Treatable Disease. Columbia University/Presbyterian Hospital, Rheumatology Grand Rounds, New York, NY, October 26, 2001.

- q. Invited panel member, Workshop on Establishing Core Set of Variables in Scleroderma Care and Research, Portonova, Italy February 2-9, 2002.
- r. Invited speaker, International Scleroderma Biannual Workshop, Woods Hole, MA, USA May 18 - 22, 2002.
- s. Annual Scleroderma Foundation Patient Conference Keynote Speaker, "Update on Scleroderma Research and Treatment," Las Vegas, NV, June 30, 2002.
- t. Invited panel member, Pew Expert Panel on a Health Tracking Network for Autoimmune Disease, sponsored by the Agency for Toxic Substances and Disease Registry (ATSDR), CDC, Atlanta Georgia, Sept. 20, 2002
- u. Invited panel member, NIH/NIAMS Workshop on Collaborative Approaches to Genetics Research in Rheumatic and Autoimmune Skin Diseases, Rockville, MD, June 22, 2003.
- v. Moderator, VIII International Workshop on Scleroderma Research, TrinityCollege, Cambridge, UK, July 31- August 4, 2004
- w. Invited speaker, Post American College of Rheumatology Symposium "Inside Scleroderma: A Focus on Cardiopulmonary Complications of Systemic Sclerosis," San Antonio, Texas, October 21, 2004
- x. Invited speaker, Annual Scleroderma Foundation Patient Conference "Update on Scleroderma Research and Treatment," Boston, MA, June 18-19, 2005.
- y. Invited speaker, NIAID/NCI Workshop on Feasibility of Allogeneic Hematopoietic stem cell transplantation for autoimmune disease, Topic: Epidemiology of Scleroderma, Bethesda, MD, March 12-13, 2005.
- z. Invited speaker, UCLA sponsored City of Hope conference on Epidemiology of SSc, Los Angeles, CA 10/6/2005.
- aa. Invited speaker, Consensus Conference on Systemic Autoimmune Rheumatic Diseases, Topic: The Clinical Trial as a Probe into Disease Mechanisms of Scleroderma, Toronto, Ontario, Canada, December 3-4, 2005.
- bb. Invited speaker, International Scientific Advisory Board Meeting (Actelion Pharmaceuticals), Athens, Greece, "Update on the Genetics of Scleroderma," April 22, 2006.
- cc. Invited speaker, 9th International Workshop for Scleroderma Research, August 5-9, 2006, Boston, MA.
- dd. Invited speaker, International Workshop on Systemic Sclerosis: Gene Polymorphisms, Clinical Variants and Response to Therapy, Milan Italy, "Genetic Polymorphisms in SSc and SLE – Lessons to be Learned." March 3-10, 2007.
- ee. Invited speaker, Professor E. Carwile LeRoy Memorial International Workshop on Scleroderma, Tokyo Japan, "The Epidemiology of Scleroderma," May 18-20, 2007.

2015 Ishmael Lectureship



- ff. Invited Speaker, American College of Rheumatology Board Review Course, Philadelphia, PA "Scleroderma" March 17, 2007.
- gg. Invited Speaker, Scleroderma Foundation National Patient Conference, Philadelphia, PA "Scleroderma 101," July 21, 2007.
- hh. Invited speaker, Stanford University Rheumatology Grand Rounds, Palo Alto, CA "The Genetics of Scleroderma: August 9, 2007.
- ii. Invited moderator, American College of Rheumatology national meeting, Boston, MA, Nov 7-11, 2007.
- jj. Invited Speaker, American College of Rheumatology Board Review Course, Atlanta, GA "Scleroderma" March 8, 2008.
- kk. Invited Speaker, 8th International Pulmonary Hypertension Forum, Barcelona, Spain, March 20-22, 2009.
- ll. Invited Speaker, PANLAR/EUSTAR course on Scleroderma: Teaching the Teachers, Sao Paulo, Brazil, May 8-11, 2008.
- mm. Invited Moderator, 10th International Workshop on Scleroderma Research, Cambridge University, Cambridge, England, August 2-6, 2008.
- nn. Invited Speaker, Puerto Rico Rheumatology Association International Meeting (PRAIM). "Update on Scleroderma Treatment in 2009" San Juan, Puerto Rico, May 28-31, 2009.
- oo. Invited Speaker, American College of Rheumatology annual meeting. "GWAS in Scleroderma" October 18, 2009.
- pp. Invited Speaker, Haematopoietic Stem Cell Transplantation for Severe Autoimmune Diseases, "The American Experience in the SCOT Trial," Florence, Italy, November 19-20, 2009.
- qq. Invited Moderator, International Scleroderma Biannual Workshop, Boston, MA, July 30- Aug 2, 2010.
- rr. Invited Moderator, First Systemic Sclerosis World Congress, Florence, Italy, Feb 11-13, 2010.
- ss. Invited Moderator, American College of Rheumatology national meeting, Atlanta, GA, Nov 6-11, 2010.
- tt. Invited Speaker, International Scleroderma Clinical Care and Research (InSCAR) meeting, Shanghai, China, Feb 20, 2011.
- uu. American College of Rheumatology Board Recertification Course Invited speaker, Dallas March 2011.
- vv. Invited Speaker, 11th International Workshop on Scleroderma Research, Cambridge University, Cambridge, England, July 23-27, 2011.
- ww. Invited Speaker, 2nd International ImmunoChip Consortium meeting, Montreal, Canada "ImmunoChip Results in Scleroderma," Oct 11, 2011.
- xx. Invited Moderator, American College of Rheumatology national meeting, Chicago, IL, Nov 6-9, 2011.

- yy. Invited Speaker, International Scleroderma Clinical Care and Research (INSCAR) meeting, Shanghai, China, Feb 12, 2012.
- zz. American College of Rheumatology Maintenance of Certification Review Course, Baltimore, MD "Scleroderma," March 18, 2012.
- aaa. Invited Speaker, Il Simposio LatinoAmericano de Esclerosis Sistemica, Bogota, Columbia, September 21 and 22, 2012.
- bbb. Invited Speaker, International Scleroderma Clinical Care and Research (INSCAR) meeting, Shanghai, China, Mar 3, 2013.
- ccc. Invited Speaker, American College of Rheumatology Maintenance of Certification Review Course, Atlanta, Ga. Mar 10, 2013.
- ddd. Invited Speaker Center for International Blood and Marrow Transplant Research (CIBMTR) Workshop on Transplant and Cellular Therapy for Autoimmune Disease, Milwaukee, WI, Apr 19, 2013.
- eee. Invited Speaker, World Scleroderma Foundation Points to Consider meeting, Florence, Italy, May 4, 2013.
- fff. Invited Moderator, International Scleroderma Research Workshop, Boston, MA, Aug 4-7, 2013.
- ggg. Invited Speaker, American College of Rheumatology Annual Meeting, San Diego, CA, October 2013.
- hhh. Invited Speaker, International Scleroderma Clinical Care and Research (INSCAR) meeting, Shijiazhuang, China, Mar 29, 2014
- iii. Invited Attendee, NIH/NIAMS Scleroderma Roundtable Discossuion of Future Directions in Scleroderma, Bethesda, MD 2/27/2015
- jjj. Invited Speaker, American College of Rheumatology Maintenance of Certification Review Course, Fort Worth, TX. Mar 9, 2014
- kkk. Invited Speaker, International Scleroderma Clinical Care and Research (INSCAR) meeting, Shijiazhuang, China, Mar 29, 2014

Presentations at Local and Regional meetings:

1. Invited speaker, Professors in Action, Michigan Chapter of the American College of Physicians annual meeting. Traverse City, MI, September 1995.
2. Invited speaker, ACR Central Regional meeting, "Therapeutic Update in Scleroderma," Chicago, IL, April 2, 1995.
3. Rheumatology Session, Michigan Chapter American College of Physicians meeting, Grand Traverse, MI, September 1988, September 1989, and September 1990 meetings.
4. "Common Problems in Rheumatology for the Practicing Physicians," Conference sponsored by Wayne State University, Southfield, MI, September 13, 1989.
5. "Update: Medical Management and Treatment of Arthritides"

- Conference sponsored by Wayne State University, Southfield, MI, September 13, 1989.
6. "Rheumatology Update, Pathogenesis and Treatment of the Rheumatic Diseases," National Conference sponsored by Wayne State University, Dearborn, MI, October 11-12, 1989.
 7. Invited speaker, Professors in Action, Michigan Chapter of the American College of Physicians annual meeting, Traverse City, MI, September, 1996.
 8. Department of Medicine, CPC, Discussant, Harper Hospital, Detroit, MI, November 27, 1996.
 9. Department of Medicine, CPC, Discussant, Harper Hospital, Detroit, MI, November 26, 1997.
 10. "Scleroderma Update," Michigan Dermatology Society annual meeting, Dearborn, MI, April 22, 1998.
 11. Invited speaker, The Cleveland Clinic, Internal Medicine and Rheumatology Grand Rounds "Scleroderma Update," Cleveland, OH, June 18, 1998.
 12. Invited speaker, The Cleveland Rheumatism Society, "Theories on the Pathogenesis of Scleroderma," Cleveland, OH, June 17, 1998.
 13. University of Michigan Rheumatology Grand Rounds, "Scleroderma: the Search for an Environmental Trigger," Ann Arbor, MI, March 5, 1999.
 14. WSU Division of Rheumatology sponsored symposium for Graduate Medical Education, "New Biologics in Rheumatoid Arthritis," Detroit, MI, May 5, 1999.
 15. University of Western Ontario Rheumatology Grand Rounds, "Therapeutic Options in Scleroderma," "Options in Scleroderma," London, Ontario, May 13, 1999.
 16. Henry Ford Hospital Department of Internal Medicine Grand Rounds, "Diagnosis and Treatment of Systemic Vasculitis," Detroit, MI, June 3, 1999.
 17. Michigan State Medical Society Meeting, Dermatology Update, "Scleroderma: Therapeutic Advances / Elusive Cure," Dearborn, MI, October 31, 2001.
 18. CPC Discussant, Department of Internal Medicine, UT-H, June 17, 2002.
 19. University of Michigan, Rheumatology Grand Rounds, "Scleroderma Clinical Trials and Tribulations," Ann Arbor, MI, October 11, 2002
 20. Symposium on Pulmonary Arterial Hypertension sponsored by the University of Michigan Pulmonary Medicine and CME sections, "Secondary causes of PAH – the Autoimmune Diseases," Livonia, MI, October 12, 2002.
 21. University of Texas – San Antonio, Internal Medicine Grand Rounds "Update on Scleroderma Treatment and Research, January 29, 2003.

22. San Antonio Area Rheumatism Society "Update on Scleroderma Therapy" January 28, 2003.
23. International Rheumatology Network sponsored "Update on Scleroderma Therapy," Minneapolis, MN May 17, 2003
24. Rheumatology on the Beach "New Modalities for Therapy in Scleroderma" Florida, September 21, 2003.
25. Scleroderma Foundation sponsored expert panel on the status of research and therapy in scleroderma, New York, NY, February 9, 2004.
26. Texas Medical Center Rheumatology Grand Rounds "Update on Treatment Trials in Scleroderma" UT-H Medical School, March 9, 2004.
27. CME meeting sponsored by UT-Houston "Approach to the SSc Patient with Dyspnea, April 29, 2004, Houston, Tx.
28. The International Pulmonary Hypertension Experts Conference "Uncovering PAH Secondary to SSc," New York, NY, June 11, 2004.
29. MD Anderson Cancer Center GVHD Conference "Current Issues in the Management of Systemic Sclerosis, Houston, TX, June 15, 2004.
30. Speaker, 4th Annual Cytokine Immunology for the 21st Century, Austin, Tx, August 21, 2004.
31. Internal Medicine for the Cancer Patient, MD Anderson sponsored conference "Autoimmune Disease and Cancer: Cause, Effect or Coincidence?" Houston, TX, September 10, 2004.
32. Rheumatology Grand Rounds, University of Washington, Seattle, November 19, 2004.
33. San Antonio Rheumatism Society meeting on 'Updates in Scleroderma', San Antonio TX 9/14/2005.
34. UT San Antonio Health Science Center presentation to Rheumatology Division 'Pathogenesis of Scleroderma' 9/15/2005.
35. Internal Medicine Grand Rounds, Houston Northwest Medical Center, "Overview of Advances in Rheumatology,' December 13, 2005.
36. Alabama Rheumatism Society meeting 'Update in Scleroderma' Birmingham, AL 1/11/2006.
37. UAB Rheumatology Grand Rounds 'The Genetics of Scleroderma' Birmingham, AL, 1/12/2006.
38. Invited Speaker, UT Southwestern Rheumatology Division, "Update on Treatment of SSc" August 25, 2006, Dallas.
39. New Orleans Rheumatism Society 'Update on SSc Treatment' New Orleans, LA 8/30/2006.
40. Invited Speaker, Ochsner Clinic, New Orleans, LA, "Update on Treatment of SSc," August 31, 2006.
41. Invited Speaker, University of Arkansas Medical Center, Department of Medicine Grand Rounds, Little Rock, AR, "Treatment of Scleroderma in 2007," January 24, 2007.

42. Invited Speaker, Baylor College of Medicine, "Management & Treatment of SSc in 2007 - Lessons from Clinical Trials, March 29, 2007.
43. Invited Speaker, West Texas Rheumatism Society, Lubbock, TX "The treatment of SSc in 2007," April 27, 2007.
44. Invited Speaker, Park Plaza Hospital, Houston, TX "The Treatment of SSc in 2007," June 13, 2007.
45. Invited Speaker, Louisiana State University, Shreveport, LA "Update on the Treatment of SSc in 2007," July 27, 2007.
46. Invited Speaker, University of Alabama Birmingham, annual Lowe Conference "Genetics and Genomics of SSc" October 5-6, 2007.
47. Invited Speaker, Georgetown University, Internal Medicine Grand Rounds "Genetics and Genomics of Scleroderma," February 13, 2008.
48. Invited Speaker, Temple University, Philadelphia, "The Rheumatologist's Approach to Pulmonary Hypertension" June 5, 2008.
49. Invited Speaker, St. Luke's Episcopal Hospital Internal Medicine Grand Rounds, Houston, TX "Update on Scleroderma Therapy 2009" November 24, 2008.
50. Invited Speaker, Methodist Hospital Internal Medicine Grand Rounds, Houston, TX "Update on Scleroderma Therapy 2009" April 28, 2009.
51. Invited Speaker, LSU Rheumatology Case Conference, New Orleans, "Scleroderma Cases" May 13, 2009.
52. Internal Medicine Grand Rounds speaker, UT-Houston "Scleroderma: Update on Diagnosis and Management for the General Internist," September, 2009.
53. Rheumatology Grand Rounds speaker, St. Louis University, St. Louis, MO. "Update on the Treatment of Scleroderma in 2010," March 26, 2010.
54. Rheumatology Case Presentations to Rheumatology Fellows, Washington University, St. Louis, MO. March 26, 2010.
55. Internal Medicine Grand Rounds speaker, Henry Ford Hospital, Detroit MI "Update on the Diagnosis and Treatment of Scleroderma," April 7, 2011.
56. Rheumatology Grand Rounds, Cedars Sinai Hospital, Los Angeles, CA "Update on the Diagnosis and Treatment of Scleroderma," June 22, 2011.
57. Internal Medicine Grand Rounds, Scott & White Clinic, Temple TX "Update on the Diagnosis and Treatment of Scleroderma," Oct 20, 2011
58. Internal Medicine Grand Rounds, Baylor-Dallas Medical Center, "Diagnosis and Treatment of Scleroderma in 2011," Nov. 22, 2011.
59. Internal Medicine Grand Rounds, The Methodist Hospital, Houston, TX, "Diagnosis and Management of Scleroderma in 2012," Jan. 10. 2012.
60. Scleroderma Center Research Conference speaker, Boston University, Boston MA "The Genetics of Systemic Sclerosis," March 2, 2012.
61. Northwest Rheumatism Society regional meeting "Update on Treatment in systemic Sclerosis (SSc)," Portland, OR April 29, 2012.

2015 Ishmael Lectureship



62. Texas Rheumatology Association "Rheumatology Round-Up" annual conference, San Antonio, Tx., "Update on the Therapy of Scleroderma," May 12, 2012.
63. Ontario Rheumatism Association Annual Meeting Plenary Speaker "The Genetics of Scleroderma," Muskoka, Ontario, Canada May 26-27, 2012.
64. Internal Medicine Grand Rounds at Texas Health Presbyterian Hospital, Dallas, TX, "The Treatment of Scleroderma in 2012: Are We Doing Better?" August 15, 2012.
65. Grand Rounds at Tomball Regional Medical Center "Raynaud's, Puffy Hands and Positive ANA: When to Consider Scleroderma and What To Do Next," September 12, 2012.
66. Rheumatology Grand Rounds, Autoimmunity Center, Feinstein Institute, North Shore University Hospital, Manhasset, NY, Mar 12, 2013.
67. Primary Care Update Conference, Oklahoma City, OK, May 17, 2013.
68. Scleroderma Foundation National Patient Conference, Atlanta, GA, 7/28/2013 "Scleroderma 101."
69. Internal Medicine Grand Rounds, St. Luke's Episcopal Hospital, Houston, 12/2/2013 "Raynaud's Phenomenon and Scleroderma for the Internist."
70. Scleroderma Foundation National Patient Conference, Anaheim, CA, 7/27/2014 "Scleroderma 101."